id	sid	tid	token	lemma	pos
work_knprvzmplre5lark3gt55of23e	1	1	Impact	impact	NN
work_knprvzmplre5lark3gt55of23e	1	2	of	of	IN
work_knprvzmplre5lark3gt55of23e	1	3	genomic	genomic	JJ
work_knprvzmplre5lark3gt55of23e	1	4	changes	change	NNS
work_knprvzmplre5lark3gt55of23e	1	5	on	on	IN
work_knprvzmplre5lark3gt55of23e	1	6	the	the	DT
work_knprvzmplre5lark3gt55of23e	1	7	treatment	treatment	NN
work_knprvzmplre5lark3gt55of23e	1	8	of	of	IN
work_knprvzmplre5lark3gt55of23e	1	9	lung	lung	NN
work_knprvzmplre5lark3gt55of23e	1	10	cancer	cancer	NN
work_knprvzmplre5lark3gt55of23e	1	11	:	:	:
work_knprvzmplre5lark3gt55of23e	1	12	MTP10	MTP10	NNP
work_knprvzmplre5lark3gt55of23e	1	13	-	-	:
work_knprvzmplre5lark3gt55of23e	1	14	01	01	CD
work_knprvzmplre5lark3gt55of23e	1	15	Journal	Journal	NNP
work_knprvzmplre5lark3gt55of23e	1	16	of	of	IN
work_knprvzmplre5lark3gt55of23e	1	17	Thoracic	Thoracic	NNP
work_knprvzmplre5lark3gt55of23e	1	18	Oncology	Oncology	NNP
work_knprvzmplre5lark3gt55of23e	1	19	•	•	NNP
work_knprvzmplre5lark3gt55of23e	1	20	Volume	volume	NN
work_knprvzmplre5lark3gt55of23e	1	21	2	2	CD
work_knprvzmplre5lark3gt55of23e	1	22	,	,	,
work_knprvzmplre5lark3gt55of23e	1	23	Number	number	NN
work_knprvzmplre5lark3gt55of23e	1	24	8	8	CD
work_knprvzmplre5lark3gt55of23e	1	25	,	,	,
work_knprvzmplre5lark3gt55of23e	1	26	Supplement	supplement	NN
work_knprvzmplre5lark3gt55of23e	1	27	4	4	CD
work_knprvzmplre5lark3gt55of23e	1	28	,	,	,
work_knprvzmplre5lark3gt55of23e	1	29	August	August	NNP
work_knprvzmplre5lark3gt55of23e	1	30	2007	2007	CD
work_knprvzmplre5lark3gt55of23e	1	31	12th	12th	JJ
work_knprvzmplre5lark3gt55of23e	1	32	World	World	NNP
work_knprvzmplre5lark3gt55of23e	1	33	Conference	Conference	NNP
work_knprvzmplre5lark3gt55of23e	1	34	on	on	IN
work_knprvzmplre5lark3gt55of23e	1	35	Lung	Lung	NNP
work_knprvzmplre5lark3gt55of23e	1	36	Cancer	Cancer	NNP
work_knprvzmplre5lark3gt55of23e	1	37	Copyright	Copyright	NNP
work_knprvzmplre5lark3gt55of23e	1	38	©	©	NNP
work_knprvzmplre5lark3gt55of23e	1	39	2007	2007	CD
work_knprvzmplre5lark3gt55of23e	1	40	by	by	IN
work_knprvzmplre5lark3gt55of23e	1	41	the	the	DT
work_knprvzmplre5lark3gt55of23e	1	42	International	International	NNP
work_knprvzmplre5lark3gt55of23e	1	43	Association	Association	NNP
work_knprvzmplre5lark3gt55of23e	1	44	for	for	IN
work_knprvzmplre5lark3gt55of23e	1	45	the	the	DT
work_knprvzmplre5lark3gt55of23e	1	46	Study	Study	NNP
work_knprvzmplre5lark3gt55of23e	1	47	of	of	IN
work_knprvzmplre5lark3gt55of23e	1	48	Lung	Lung	NNP
work_knprvzmplre5lark3gt55of23e	1	49	CancerS276	CancerS276	NNP
work_knprvzmplre5lark3gt55of23e	1	50	MTP10	MTP10	NNP
work_knprvzmplre5lark3gt55of23e	1	51	-	-	:
work_knprvzmplre5lark3gt55of23e	1	52	01	01	CD
work_knprvzmplre5lark3gt55of23e	1	53	EGFR	egfr	NN
work_knprvzmplre5lark3gt55of23e	1	54	-	-	HYPH
work_knprvzmplre5lark3gt55of23e	1	55	Targeted	target	VBN
work_knprvzmplre5lark3gt55of23e	1	56	Therapy	Therapy	NNP
work_knprvzmplre5lark3gt55of23e	1	57	,	,	,
work_knprvzmplre5lark3gt55of23e	1	58	Tue	Tue	NNP
work_knprvzmplre5lark3gt55of23e	1	59	,	,	,
work_knprvzmplre5lark3gt55of23e	1	60	Sept	Sept	NNP
work_knprvzmplre5lark3gt55of23e	1	61	4	4	CD
work_knprvzmplre5lark3gt55of23e	1	62	,	,	,
work_knprvzmplre5lark3gt55of23e	1	63	07:00	07:00	CD
work_knprvzmplre5lark3gt55of23e	1	64	-	-	HYPH
work_knprvzmplre5lark3gt55of23e	1	65	08:00	08:00	CD
work_knprvzmplre5lark3gt55of23e	1	66	Impact	impact	NN
work_knprvzmplre5lark3gt55of23e	1	67	of	of	IN
work_knprvzmplre5lark3gt55of23e	1	68	genomic	genomic	JJ
work_knprvzmplre5lark3gt55of23e	1	69	changes	change	NNS
work_knprvzmplre5lark3gt55of23e	1	70	on	on	IN
work_knprvzmplre5lark3gt55of23e	1	71	the	the	DT
work_knprvzmplre5lark3gt55of23e	1	72	treatment	treatment	NN
work_knprvzmplre5lark3gt55of23e	1	73	of	of	IN
work_knprvzmplre5lark3gt55of23e	1	74	lung	lung	NN
work_knprvzmplre5lark3gt55of23e	1	75	cancer	cancer	NN
work_knprvzmplre5lark3gt55of23e	1	76	Johnson	Johnson	NNP
work_knprvzmplre5lark3gt55of23e	1	77	,	,	,
work_knprvzmplre5lark3gt55of23e	1	78	Bruce	Bruce	NNP
work_knprvzmplre5lark3gt55of23e	1	79	E.	E.	NNP
work_knprvzmplre5lark3gt55of23e	1	80	Dana	Dana	NNP
work_knprvzmplre5lark3gt55of23e	1	81	-	-	HYPH
work_knprvzmplre5lark3gt55of23e	1	82	Farber	Farber	NNP
work_knprvzmplre5lark3gt55of23e	1	83	Cancer	Cancer	NNP
work_knprvzmplre5lark3gt55of23e	1	84	Institute	Institute	NNP
work_knprvzmplre5lark3gt55of23e	1	85	,	,	,
work_knprvzmplre5lark3gt55of23e	1	86	Brigham	Brigham	NNP
work_knprvzmplre5lark3gt55of23e	1	87	and	and	CC
work_knprvzmplre5lark3gt55of23e	1	88	Women	Women	NNP
work_knprvzmplre5lark3gt55of23e	1	89	’s	’s	POS
work_knprvzmplre5lark3gt55of23e	1	90	Hospital	Hospital	NNP
work_knprvzmplre5lark3gt55of23e	1	91	,	,	,
work_knprvzmplre5lark3gt55of23e	1	92	Harvard	Harvard	NNP
work_knprvzmplre5lark3gt55of23e	1	93	Medical	Medical	NNP
work_knprvzmplre5lark3gt55of23e	1	94	School	School	NNP
work_knprvzmplre5lark3gt55of23e	1	95	,	,	,
work_knprvzmplre5lark3gt55of23e	1	96	Boston	Boston	NNP
work_knprvzmplre5lark3gt55of23e	1	97	,	,	,
work_knprvzmplre5lark3gt55of23e	1	98	MA	MA	NNP
work_knprvzmplre5lark3gt55of23e	1	99	,	,	,
work_knprvzmplre5lark3gt55of23e	1	100	USA	USA	NNP
work_knprvzmplre5lark3gt55of23e	1	101	Three	three	CD
work_knprvzmplre5lark3gt55of23e	1	102	years	year	NNS
work_knprvzmplre5lark3gt55of23e	1	103	have	have	VBP
work_knprvzmplre5lark3gt55of23e	1	104	passed	pass	VBN
work_knprvzmplre5lark3gt55of23e	1	105	since	since	IN
work_knprvzmplre5lark3gt55of23e	1	106	mutations	mutation	NNS
work_knprvzmplre5lark3gt55of23e	1	107	of	of	IN
work_knprvzmplre5lark3gt55of23e	1	108	the	the	DT
work_knprvzmplre5lark3gt55of23e	1	109	tyrosine	tyrosine	JJ
work_knprvzmplre5lark3gt55of23e	1	110	kinase	kinase	NN
work_knprvzmplre5lark3gt55of23e	1	111	domain	domain	NN
work_knprvzmplre5lark3gt55of23e	1	112	of	of	IN
work_knprvzmplre5lark3gt55of23e	1	113	the	the	DT
work_knprvzmplre5lark3gt55of23e	1	114	epidermal	epidermal	JJ
work_knprvzmplre5lark3gt55of23e	1	115	growth	growth	NN
work_knprvzmplre5lark3gt55of23e	1	116	factor	factor	NN
work_knprvzmplre5lark3gt55of23e	1	117	receptor	receptor	NN
work_knprvzmplre5lark3gt55of23e	1	118	(	(	-LRB-
work_knprvzmplre5lark3gt55of23e	1	119	EGFR	egfr	NN
work_knprvzmplre5lark3gt55of23e	1	120	)	)	-RRB-
work_knprvzmplre5lark3gt55of23e	1	121	were	be	VBD
work_knprvzmplre5lark3gt55of23e	1	122	discovered	discover	VBN
work_knprvzmplre5lark3gt55of23e	1	123	in	in	IN
work_knprvzmplre5lark3gt55of23e	1	124	patients	patient	NNS
work_knprvzmplre5lark3gt55of23e	1	125	with	with	IN
work_knprvzmplre5lark3gt55of23e	1	126	lung	lung	NN
work_knprvzmplre5lark3gt55of23e	1	127	cancer	cancer	NN
work_knprvzmplre5lark3gt55of23e	1	128	who	who	WP
work_knprvzmplre5lark3gt55of23e	1	129	had	have	VBD
work_knprvzmplre5lark3gt55of23e	1	130	dramatic	dramatic	JJ
work_knprvzmplre5lark3gt55of23e	1	131	clinical	clinical	JJ
work_knprvzmplre5lark3gt55of23e	1	132	responses	response	NNS
work_knprvzmplre5lark3gt55of23e	1	133	to	to	IN
work_knprvzmplre5lark3gt55of23e	1	134	treat-	treat-	JJ
work_knprvzmplre5lark3gt55of23e	1	135	ment	ment	NN
work_knprvzmplre5lark3gt55of23e	1	136	with	with	IN
work_knprvzmplre5lark3gt55of23e	1	137	gefitinib	gefitinib	NNP
work_knprvzmplre5lark3gt55of23e	1	138	.	.	.
work_knprvzmplre5lark3gt55of23e	2	1	Additional	additional	JJ
work_knprvzmplre5lark3gt55of23e	2	2	laboratory	laboratory	NN
work_knprvzmplre5lark3gt55of23e	2	3	and	and	CC
work_knprvzmplre5lark3gt55of23e	2	4	clinical	clinical	JJ
work_knprvzmplre5lark3gt55of23e	2	5	studies	study	NNS
work_knprvzmplre5lark3gt55of23e	2	6	have	have	VBP
work_knprvzmplre5lark3gt55of23e	2	7	provided	provide	VBN
work_knprvzmplre5lark3gt55of23e	2	8	further	further	JJ
work_knprvzmplre5lark3gt55of23e	2	9	insights	insight	NNS
work_knprvzmplre5lark3gt55of23e	2	10	into	into	IN
work_knprvzmplre5lark3gt55of23e	2	11	the	the	DT
work_knprvzmplre5lark3gt55of23e	2	12	biological	biological	JJ
work_knprvzmplre5lark3gt55of23e	2	13	impact	impact	NN
work_knprvzmplre5lark3gt55of23e	2	14	of	of	IN
work_knprvzmplre5lark3gt55of23e	2	15	EGFR	egfr	NN
work_knprvzmplre5lark3gt55of23e	2	16	mutations	mutation	NNS
work_knprvzmplre5lark3gt55of23e	2	17	in	in	IN
work_knprvzmplre5lark3gt55of23e	2	18	cell	cell	NN
work_knprvzmplre5lark3gt55of23e	2	19	culture	culture	NN
work_knprvzmplre5lark3gt55of23e	2	20	experiments	experiment	NNS
work_knprvzmplre5lark3gt55of23e	2	21	and	and	CC
work_knprvzmplre5lark3gt55of23e	2	22	in	in	IN
work_knprvzmplre5lark3gt55of23e	2	23	patients	patient	NNS
work_knprvzmplre5lark3gt55of23e	2	24	with	with	IN
work_knprvzmplre5lark3gt55of23e	2	25	lung	lung	NN
work_knprvzmplre5lark3gt55of23e	2	26	cancer	cancer	NN
work_knprvzmplre5lark3gt55of23e	2	27	.	.	.
work_knprvzmplre5lark3gt55of23e	3	1	In	in	IN
work_knprvzmplre5lark3gt55of23e	3	2	vitro	vitro	FW
work_knprvzmplre5lark3gt55of23e	3	3	characterizations	characterization	NNS
work_knprvzmplre5lark3gt55of23e	3	4	of	of	IN
work_knprvzmplre5lark3gt55of23e	3	5	lung	lung	NN
work_knprvzmplre5lark3gt55of23e	3	6	cancer	cancer	NN
work_knprvzmplre5lark3gt55of23e	3	7	cell	cell	NN
work_knprvzmplre5lark3gt55of23e	3	8	lines	line	NNS
work_knprvzmplre5lark3gt55of23e	3	9	and	and	CC
work_knprvzmplre5lark3gt55of23e	3	10	host	host	NN
work_knprvzmplre5lark3gt55of23e	3	11	cell	cell	NN
work_knprvzmplre5lark3gt55of23e	3	12	lines	line	NNS
work_knprvzmplre5lark3gt55of23e	3	13	transfected	transfecte	VBN
work_knprvzmplre5lark3gt55of23e	3	14	with	with	IN
work_knprvzmplre5lark3gt55of23e	3	15	these	these	DT
work_knprvzmplre5lark3gt55of23e	3	16	mutant	mutant	JJ
work_knprvzmplre5lark3gt55of23e	3	17	and	and	CC
work_knprvzmplre5lark3gt55of23e	3	18	wild	wild	JJ
work_knprvzmplre5lark3gt55of23e	3	19	type	type	NN
work_knprvzmplre5lark3gt55of23e	3	20	EGFRs	EGFRs	NNP
work_knprvzmplre5lark3gt55of23e	3	21	show	show	VBP
work_knprvzmplre5lark3gt55of23e	3	22	most	most	JJS
work_knprvzmplre5lark3gt55of23e	3	23	cell	cell	NN
work_knprvzmplre5lark3gt55of23e	3	24	lines	line	NNS
work_knprvzmplre5lark3gt55of23e	3	25	with	with	IN
work_knprvzmplre5lark3gt55of23e	3	26	mu-	mu-	NNP
work_knprvzmplre5lark3gt55of23e	3	27	tated	tat	VBN
work_knprvzmplre5lark3gt55of23e	3	28	EGFRs	EGFRs	NNP
work_knprvzmplre5lark3gt55of23e	3	29	are	be	VBP
work_knprvzmplre5lark3gt55of23e	3	30	growth	growth	NN
work_knprvzmplre5lark3gt55of23e	3	31	inhibited	inhibit	VBN
work_knprvzmplre5lark3gt55of23e	3	32	by	by	IN
work_knprvzmplre5lark3gt55of23e	3	33	10	10	CD
work_knprvzmplre5lark3gt55of23e	3	34	-	-	SYM
work_knprvzmplre5lark3gt55of23e	3	35	100	100	CD
work_knprvzmplre5lark3gt55of23e	3	36	fold	fold	VBP
work_knprvzmplre5lark3gt55of23e	3	37	lower	low	JJR
work_knprvzmplre5lark3gt55of23e	3	38	concentrations	concentration	NNS
work_knprvzmplre5lark3gt55of23e	3	39	of	of	IN
work_knprvzmplre5lark3gt55of23e	3	40	gefitinib	gefitinib	NNP
work_knprvzmplre5lark3gt55of23e	3	41	and	and	CC
work_knprvzmplre5lark3gt55of23e	3	42	erlotinib	erlotinib	NNP
work_knprvzmplre5lark3gt55of23e	3	43	(	(	-LRB-
work_knprvzmplre5lark3gt55of23e	3	44	10	10	CD
work_knprvzmplre5lark3gt55of23e	3	45	-	-	SYM
work_knprvzmplre5lark3gt55of23e	3	46	100	100	CD
work_knprvzmplre5lark3gt55of23e	3	47	nM	nM	NNP
work_knprvzmplre5lark3gt55of23e	3	48	)	)	-RRB-
work_knprvzmplre5lark3gt55of23e	3	49	compared	compare	VBN
work_knprvzmplre5lark3gt55of23e	3	50	to	to	IN
work_knprvzmplre5lark3gt55of23e	3	51	wild	wild	JJ
work_knprvzmplre5lark3gt55of23e	3	52	type	type	NN
work_knprvzmplre5lark3gt55of23e	3	53	EGFR	egfr	NN
work_knprvzmplre5lark3gt55of23e	3	54	(	(	-LRB-
work_knprvzmplre5lark3gt55of23e	3	55	Approximately	approximately	RB
work_knprvzmplre5lark3gt55of23e	3	56	1	1	CD
work_knprvzmplre5lark3gt55of23e	3	57	-	-	SYM
work_knprvzmplre5lark3gt55of23e	3	58	5	5	CD
work_knprvzmplre5lark3gt55of23e	3	59	uM	um	UH
work_knprvzmplre5lark3gt55of23e	3	60	)	)	-RRB-
work_knprvzmplre5lark3gt55of23e	3	61	.	.	.
work_knprvzmplre5lark3gt55of23e	4	1	Lung	lung	NN
work_knprvzmplre5lark3gt55of23e	4	2	cancer	cancer	NN
work_knprvzmplre5lark3gt55of23e	4	3	cell	cell	NN
work_knprvzmplre5lark3gt55of23e	4	4	lines	line	NNS
work_knprvzmplre5lark3gt55of23e	4	5	with	with	IN
work_knprvzmplre5lark3gt55of23e	4	6	mutations	mutation	NNS
work_knprvzmplre5lark3gt55of23e	4	7	of	of	IN
work_knprvzmplre5lark3gt55of23e	4	8	the	the	DT
work_knprvzmplre5lark3gt55of23e	4	9	EGFR	egfr	NN
work_knprvzmplre5lark3gt55of23e	4	10	treated	treat	VBN
work_knprvzmplre5lark3gt55of23e	4	11	with	with	IN
work_knprvzmplre5lark3gt55of23e	4	12	concentrations	concentration	NNS
work_knprvzmplre5lark3gt55of23e	4	13	of	of	IN
work_knprvzmplre5lark3gt55of23e	4	14	gefitinib	gefitinib	NNP
work_knprvzmplre5lark3gt55of23e	4	15	and	and	CC
work_knprvzmplre5lark3gt55of23e	4	16	erlotinib	erlotinib	NNP
work_knprvzmplre5lark3gt55of23e	4	17	that	that	WDT
work_knprvzmplre5lark3gt55of23e	4	18	are	be	VBP
work_knprvzmplre5lark3gt55of23e	4	19	achievable	achievable	JJ
work_knprvzmplre5lark3gt55of23e	4	20	in	in	IN
work_knprvzmplre5lark3gt55of23e	4	21	the	the	DT
work_knprvzmplre5lark3gt55of23e	4	22	plasma	plasma	NN
work_knprvzmplre5lark3gt55of23e	4	23	undergo	undergo	VBP
work_knprvzmplre5lark3gt55of23e	4	24	apoptosis	apoptosis	NN
work_knprvzmplre5lark3gt55of23e	4	25	rather	rather	RB
work_knprvzmplre5lark3gt55of23e	4	26	than	than	IN
work_knprvzmplre5lark3gt55of23e	4	27	growth	growth	NN
work_knprvzmplre5lark3gt55of23e	4	28	arrest	arrest	NN
work_knprvzmplre5lark3gt55of23e	4	29	.	.	.
work_knprvzmplre5lark3gt55of23e	5	1	The	the	DT
work_knprvzmplre5lark3gt55of23e	5	2	other	other	JJ
work_knprvzmplre5lark3gt55of23e	5	3	common	common	JJ
work_knprvzmplre5lark3gt55of23e	5	4	genomic	genomic	JJ
work_knprvzmplre5lark3gt55of23e	5	5	changes	change	NNS
work_knprvzmplre5lark3gt55of23e	5	6	that	that	WDT
work_knprvzmplre5lark3gt55of23e	5	7	arise	arise	VBP
work_knprvzmplre5lark3gt55of23e	5	8	in	in	IN
work_knprvzmplre5lark3gt55of23e	5	9	adenocarcinomas	adenocarcinomas	NNP
work_knprvzmplre5lark3gt55of23e	5	10	of	of	IN
work_knprvzmplre5lark3gt55of23e	5	11	the	the	DT
work_knprvzmplre5lark3gt55of23e	5	12	lung	lung	NN
work_knprvzmplre5lark3gt55of23e	5	13	that	that	WDT
work_knprvzmplre5lark3gt55of23e	5	14	have	have	VBP
work_knprvzmplre5lark3gt55of23e	5	15	an	an	DT
work_knprvzmplre5lark3gt55of23e	5	16	impact	impact	NN
work_knprvzmplre5lark3gt55of23e	5	17	on	on	IN
work_knprvzmplre5lark3gt55of23e	5	18	tyrosine	tyrosine	JJ
work_knprvzmplre5lark3gt55of23e	5	19	kinase	kinase	NN
work_knprvzmplre5lark3gt55of23e	5	20	inhibitors	inhibitor	NNS
work_knprvzmplre5lark3gt55of23e	5	21	and	and	CC
work_knprvzmplre5lark3gt55of23e	5	22	other	other	JJ
work_knprvzmplre5lark3gt55of23e	5	23	targeted	target	VBN
work_knprvzmplre5lark3gt55of23e	5	24	agents	agent	NNS
work_knprvzmplre5lark3gt55of23e	5	25	include	include	VBP
work_knprvzmplre5lark3gt55of23e	5	26	KRAS	KRAS	NNP
work_knprvzmplre5lark3gt55of23e	5	27	,	,	,
work_knprvzmplre5lark3gt55of23e	5	28	BRAF	BRAF	NNP
work_knprvzmplre5lark3gt55of23e	5	29	,	,	,
work_knprvzmplre5lark3gt55of23e	5	30	and	and	CC
work_knprvzmplre5lark3gt55of23e	5	31	LKB1	LKB1	NNP
work_knprvzmplre5lark3gt55of23e	5	32	.	.	.
work_knprvzmplre5lark3gt55of23e	6	1	Prospective	prospective	JJ
work_knprvzmplre5lark3gt55of23e	6	2	studies	study	NNS
work_knprvzmplre5lark3gt55of23e	6	3	of	of	IN
work_knprvzmplre5lark3gt55of23e	6	4	lung	lung	NN
work_knprvzmplre5lark3gt55of23e	6	5	cancer	cancer	NN
work_knprvzmplre5lark3gt55of23e	6	6	patients	patient	NNS
work_knprvzmplre5lark3gt55of23e	6	7	with	with	IN
work_knprvzmplre5lark3gt55of23e	6	8	EGFR	EGFR	NNP
work_knprvzmplre5lark3gt55of23e	6	9	mutations	mutation	NNS
work_knprvzmplre5lark3gt55of23e	6	10	treated	treat	VBN
work_knprvzmplre5lark3gt55of23e	6	11	with	with	IN
work_knprvzmplre5lark3gt55of23e	6	12	gefitinib	gefitinib	NNP
work_knprvzmplre5lark3gt55of23e	6	13	and	and	CC
work_knprvzmplre5lark3gt55of23e	6	14	erlotinib	erlotinib	NNP
work_knprvzmplre5lark3gt55of23e	6	15	have	have	VBP
work_knprvzmplre5lark3gt55of23e	6	16	reported	report	VBN
work_knprvzmplre5lark3gt55of23e	6	17	a	a	DT
work_knprvzmplre5lark3gt55of23e	6	18	close	close	JJ
work_knprvzmplre5lark3gt55of23e	6	19	association	association	NN
work_knprvzmplre5lark3gt55of23e	6	20	between	between	IN
work_knprvzmplre5lark3gt55of23e	6	21	EGFR	EGFR	NNP
work_knprvzmplre5lark3gt55of23e	6	22	mutations	mutation	NNS
work_knprvzmplre5lark3gt55of23e	6	23	,	,	,
work_knprvzmplre5lark3gt55of23e	6	24	increased	increase	VBN
work_knprvzmplre5lark3gt55of23e	6	25	chance	chance	NN
work_knprvzmplre5lark3gt55of23e	6	26	of	of	IN
work_knprvzmplre5lark3gt55of23e	6	27	clinical	clinical	JJ
work_knprvzmplre5lark3gt55of23e	6	28	response	response	NN
work_knprvzmplre5lark3gt55of23e	6	29	and	and	CC
work_knprvzmplre5lark3gt55of23e	6	30	longer	long	JJR
work_knprvzmplre5lark3gt55of23e	6	31	survival	survival	NN
work_knprvzmplre5lark3gt55of23e	6	32	.	.	.
work_knprvzmplre5lark3gt55of23e	7	1	Patients	patient	NNS
work_knprvzmplre5lark3gt55of23e	7	2	with	with	IN
work_knprvzmplre5lark3gt55of23e	7	3	EGFR	egfr	NN
work_knprvzmplre5lark3gt55of23e	7	4	mutations	mutation	NNS
work_knprvzmplre5lark3gt55of23e	7	5	treated	treat	VBN
work_knprvzmplre5lark3gt55of23e	7	6	with	with	IN
work_knprvzmplre5lark3gt55of23e	7	7	gefitinib	gefitinib	NNP
work_knprvzmplre5lark3gt55of23e	7	8	or	or	CC
work_knprvzmplre5lark3gt55of23e	7	9	erlotinib	erlotinib	NNP
work_knprvzmplre5lark3gt55of23e	7	10	have	have	VBP
work_knprvzmplre5lark3gt55of23e	7	11	a	a	DT
work_knprvzmplre5lark3gt55of23e	7	12	response	response	NN
work_knprvzmplre5lark3gt55of23e	7	13	rate	rate	NN
work_knprvzmplre5lark3gt55of23e	7	14	of	of	IN
work_knprvzmplre5lark3gt55of23e	7	15	approximately	approximately	RB
work_knprvzmplre5lark3gt55of23e	7	16	80	80	CD
work_knprvzmplre5lark3gt55of23e	7	17	%	%	NN
work_knprvzmplre5lark3gt55of23e	7	18	,	,	,
work_knprvzmplre5lark3gt55of23e	7	19	a	a	DT
work_knprvzmplre5lark3gt55of23e	7	20	median	median	JJ
work_knprvzmplre5lark3gt55of23e	7	21	time	time	NN
work_knprvzmplre5lark3gt55of23e	7	22	to	to	IN
work_knprvzmplre5lark3gt55of23e	7	23	progression	progression	VB
work_knprvzmplre5lark3gt55of23e	7	24	in	in	IN
work_knprvzmplre5lark3gt55of23e	7	25	excess	excess	NN
work_knprvzmplre5lark3gt55of23e	7	26	of	of	IN
work_knprvzmplre5lark3gt55of23e	7	27	approximately	approximately	RB
work_knprvzmplre5lark3gt55of23e	7	28	one	one	CD
work_knprvzmplre5lark3gt55of23e	7	29	year	year	NN
work_knprvzmplre5lark3gt55of23e	7	30	,	,	,
work_knprvzmplre5lark3gt55of23e	7	31	and	and	CC
work_knprvzmplre5lark3gt55of23e	7	32	a	a	DT
work_knprvzmplre5lark3gt55of23e	7	33	median	median	JJ
work_knprvzmplre5lark3gt55of23e	7	34	survival	survival	NN
work_knprvzmplre5lark3gt55of23e	7	35	in	in	IN
work_knprvzmplre5lark3gt55of23e	7	36	excess	excess	NN
work_knprvzmplre5lark3gt55of23e	7	37	of	of	IN
work_knprvzmplre5lark3gt55of23e	7	38	two	two	CD
work_knprvzmplre5lark3gt55of23e	7	39	years	year	NNS
work_knprvzmplre5lark3gt55of23e	7	40	.	.	.
work_knprvzmplre5lark3gt55of23e	8	1	This	this	DT
work_knprvzmplre5lark3gt55of23e	8	2	has	have	VBZ
work_knprvzmplre5lark3gt55of23e	8	3	led	lead	VBN
work_knprvzmplre5lark3gt55of23e	8	4	to	to	IN
work_knprvzmplre5lark3gt55of23e	8	5	the	the	DT
work_knprvzmplre5lark3gt55of23e	8	6	development	development	NN
work_knprvzmplre5lark3gt55of23e	8	7	of	of	IN
work_knprvzmplre5lark3gt55of23e	8	8	commercial	commercial	JJ
work_knprvzmplre5lark3gt55of23e	8	9	tests	test	NNS
work_knprvzmplre5lark3gt55of23e	8	10	to	to	TO
work_knprvzmplre5lark3gt55of23e	8	11	determine	determine	VB
work_knprvzmplre5lark3gt55of23e	8	12	if	if	IN
work_knprvzmplre5lark3gt55of23e	8	13	the	the	DT
work_knprvzmplre5lark3gt55of23e	8	14	DNA	dna	NN
work_knprvzmplre5lark3gt55of23e	8	15	from	from	IN
work_knprvzmplre5lark3gt55of23e	8	16	tumors	tumor	NNS
work_knprvzmplre5lark3gt55of23e	8	17	retrieved	retrieve	VBN
work_knprvzmplre5lark3gt55of23e	8	18	from	from	IN
work_knprvzmplre5lark3gt55of23e	8	19	patients	patient	NNS
work_knprvzmplre5lark3gt55of23e	8	20	with	with	IN
work_knprvzmplre5lark3gt55of23e	8	21	adenocarcinoma	adenocarcinoma	NNP
work_knprvzmplre5lark3gt55of23e	8	22	have	have	VBP
work_knprvzmplre5lark3gt55of23e	8	23	a	a	DT
work_knprvzmplre5lark3gt55of23e	8	24	mutation	mutation	NN
work_knprvzmplre5lark3gt55of23e	8	25	of	of	IN
work_knprvzmplre5lark3gt55of23e	8	26	the	the	DT
work_knprvzmplre5lark3gt55of23e	8	27	EGFR	egfr	NN
work_knprvzmplre5lark3gt55of23e	8	28	.	.	.
work_knprvzmplre5lark3gt55of23e	9	1	The	the	DT
work_knprvzmplre5lark3gt55of23e	9	2	genomic	genomic	JJ
work_knprvzmplre5lark3gt55of23e	9	3	change	change	NN
work_knprvzmplre5lark3gt55of23e	9	4	associated	associate	VBN
work_knprvzmplre5lark3gt55of23e	9	5	with	with	IN
work_knprvzmplre5lark3gt55of23e	9	6	resistance	resistance	NN
work_knprvzmplre5lark3gt55of23e	9	7	to	to	IN
work_knprvzmplre5lark3gt55of23e	9	8	treatment	treatment	NN
work_knprvzmplre5lark3gt55of23e	9	9	with	with	IN
work_knprvzmplre5lark3gt55of23e	9	10	gefinib	gefinib	NNP
work_knprvzmplre5lark3gt55of23e	9	11	and	and	CC
work_knprvzmplre5lark3gt55of23e	9	12	erlotinib	erlotinib	NNP
work_knprvzmplre5lark3gt55of23e	9	13	is	be	VBZ
work_knprvzmplre5lark3gt55of23e	9	14	a	a	DT
work_knprvzmplre5lark3gt55of23e	9	15	DNA	dna	NN
work_knprvzmplre5lark3gt55of23e	9	16	mutation	mutation	NN
work_knprvzmplre5lark3gt55of23e	9	17	which	which	WDT
work_knprvzmplre5lark3gt55of23e	9	18	changes	change	VBZ
work_knprvzmplre5lark3gt55of23e	9	19	the	the	DT
work_knprvzmplre5lark3gt55of23e	9	20	threonine	threonine	NN
work_knprvzmplre5lark3gt55of23e	9	21	to	to	TO
work_knprvzmplre5lark3gt55of23e	9	22	methionine	methionine	VB
work_knprvzmplre5lark3gt55of23e	9	23	at	at	IN
work_knprvzmplre5lark3gt55of23e	9	24	the	the	DT
work_knprvzmplre5lark3gt55of23e	9	25	790th	790th	JJ
work_knprvzmplre5lark3gt55of23e	9	26	amino	amino	NN
work_knprvzmplre5lark3gt55of23e	9	27	acid	acid	NN
work_knprvzmplre5lark3gt55of23e	9	28	of	of	IN
work_knprvzmplre5lark3gt55of23e	9	29	EGFR	egfr	NN
work_knprvzmplre5lark3gt55of23e	9	30	known	know	VBN
work_knprvzmplre5lark3gt55of23e	9	31	as	as	IN
work_knprvzmplre5lark3gt55of23e	9	32	the	the	DT
work_knprvzmplre5lark3gt55of23e	9	33	(	(	-LRB-
work_knprvzmplre5lark3gt55of23e	9	34	T790	T790	NNP
work_knprvzmplre5lark3gt55of23e	9	35	M	M	NNP
work_knprvzmplre5lark3gt55of23e	9	36	)	)	-RRB-
work_knprvzmplre5lark3gt55of23e	9	37	mutation	mutation	NN
work_knprvzmplre5lark3gt55of23e	9	38	as	as	RB
work_knprvzmplre5lark3gt55of23e	9	39	well	well	RB
work_knprvzmplre5lark3gt55of23e	9	40	as	as	IN
work_knprvzmplre5lark3gt55of23e	9	41	amplification	amplification	NN
work_knprvzmplre5lark3gt55of23e	9	42	of	of	IN
work_knprvzmplre5lark3gt55of23e	9	43	the	the	DT
work_knprvzmplre5lark3gt55of23e	9	44	MET	MET	NNP
work_knprvzmplre5lark3gt55of23e	9	45	oncogene	oncogene	NN
work_knprvzmplre5lark3gt55of23e	9	46	.	.	.
work_knprvzmplre5lark3gt55of23e	10	1	Irreversible	irreversible	JJ
work_knprvzmplre5lark3gt55of23e	10	2	in-	in-	JJ
work_knprvzmplre5lark3gt55of23e	10	3	hibitors	hibitor	NNS
work_knprvzmplre5lark3gt55of23e	10	4	including	include	VBG
work_knprvzmplre5lark3gt55of23e	10	5	HKI-272	hki-272	ADD
work_knprvzmplre5lark3gt55of23e	10	6	and	and	CC
work_knprvzmplre5lark3gt55of23e	10	7	PF-299804	PF-299804	NNP
work_knprvzmplre5lark3gt55of23e	10	8	can	can	MD
work_knprvzmplre5lark3gt55of23e	10	9	cause	cause	VB
work_knprvzmplre5lark3gt55of23e	10	10	growth	growth	NN
work_knprvzmplre5lark3gt55of23e	10	11	inhibition	inhibition	NN
work_knprvzmplre5lark3gt55of23e	10	12	in	in	IN
work_knprvzmplre5lark3gt55of23e	10	13	NSCLC	nsclc	JJ
work_knprvzmplre5lark3gt55of23e	10	14	cell	cell	NN
work_knprvzmplre5lark3gt55of23e	10	15	lines	line	NNS
work_knprvzmplre5lark3gt55of23e	10	16	with	with	IN
work_knprvzmplre5lark3gt55of23e	10	17	both	both	CC
work_knprvzmplre5lark3gt55of23e	10	18	the	the	DT
work_knprvzmplre5lark3gt55of23e	10	19	resistance	resistance	NN
work_knprvzmplre5lark3gt55of23e	10	20	and	and	CC
work_knprvzmplre5lark3gt55of23e	10	21	sensitizing	sensitizing	NN
work_knprvzmplre5lark3gt55of23e	10	22	mutations	mutation	NNS
work_knprvzmplre5lark3gt55of23e	10	23	,	,	,
work_knprvzmplre5lark3gt55of23e	10	24	while	while	IN
work_knprvzmplre5lark3gt55of23e	10	25	gefitinib	gefitinib	NNP
work_knprvzmplre5lark3gt55of23e	10	26	and	and	CC
work_knprvzmplre5lark3gt55of23e	10	27	erlotinib	erlotinib	NNP
work_knprvzmplre5lark3gt55of23e	10	28	do	do	VBP
work_knprvzmplre5lark3gt55of23e	10	29	not	not	RB
work_knprvzmplre5lark3gt55of23e	10	30	.	.	.
work_knprvzmplre5lark3gt55of23e	11	1	HKI-272	hki-272	UH
work_knprvzmplre5lark3gt55of23e	11	2	and	and	CC
work_knprvzmplre5lark3gt55of23e	11	3	PF-299804	PF-299804	NNP
work_knprvzmplre5lark3gt55of23e	11	4	entered	enter	VBD
work_knprvzmplre5lark3gt55of23e	11	5	directed	directed	JJ
work_knprvzmplre5lark3gt55of23e	11	6	phase	phase	NN
work_knprvzmplre5lark3gt55of23e	11	7	I	-PRON-	PRP
work_knprvzmplre5lark3gt55of23e	11	8	and	and	CC
work_knprvzmplre5lark3gt55of23e	11	9	phase	phase	VB
work_knprvzmplre5lark3gt55of23e	11	10	II	ii	CD
work_knprvzmplre5lark3gt55of23e	11	11	trials	trial	NNS
work_knprvzmplre5lark3gt55of23e	11	12	in	in	IN
work_knprvzmplre5lark3gt55of23e	11	13	patients	patient	NNS
work_knprvzmplre5lark3gt55of23e	11	14	previously	previously	RB
work_knprvzmplre5lark3gt55of23e	11	15	treated	treat	VBN
work_knprvzmplre5lark3gt55of23e	11	16	with	with	IN
work_knprvzmplre5lark3gt55of23e	11	17	gefitinib	gefitinib	NNP
work_knprvzmplre5lark3gt55of23e	11	18	and	and	CC
work_knprvzmplre5lark3gt55of23e	11	19	erlotinib	erlotinib	NNP
work_knprvzmplre5lark3gt55of23e	11	20	and	and	CC
work_knprvzmplre5lark3gt55of23e	11	21	we	-PRON-	PRP
work_knprvzmplre5lark3gt55of23e	11	22	await	await	VBP
work_knprvzmplre5lark3gt55of23e	11	23	the	the	DT
work_knprvzmplre5lark3gt55of23e	11	24	results	result	NNS
work_knprvzmplre5lark3gt55of23e	11	25	of	of	IN
work_knprvzmplre5lark3gt55of23e	11	26	the	the	DT
work_knprvzmplre5lark3gt55of23e	11	27	trials	trial	NNS
work_knprvzmplre5lark3gt55of23e	11	28	.	.	.
work_knprvzmplre5lark3gt55of23e	12	1	MTP11	mtp11	NN
work_knprvzmplre5lark3gt55of23e	12	2	-	-	HYPH
work_knprvzmplre5lark3gt55of23e	12	3	01	01	CD
work_knprvzmplre5lark3gt55of23e	12	4	Pulmonary	Pulmonary	NNP
work_knprvzmplre5lark3gt55of23e	12	5	Toxicity	Toxicity	NNP
work_knprvzmplre5lark3gt55of23e	12	6	of	of	IN
work_knprvzmplre5lark3gt55of23e	12	7	Therapy	Therapy	NNP
work_knprvzmplre5lark3gt55of23e	12	8	,	,	,
work_knprvzmplre5lark3gt55of23e	12	9	Tue	Tue	NNP
work_knprvzmplre5lark3gt55of23e	12	10	,	,	,
work_knprvzmplre5lark3gt55of23e	12	11	Sept	Sept	NNP
work_knprvzmplre5lark3gt55of23e	12	12	4	4	CD
work_knprvzmplre5lark3gt55of23e	12	13	,	,	,
work_knprvzmplre5lark3gt55of23e	12	14	07:00	07:00	CD
work_knprvzmplre5lark3gt55of23e	12	15	-	-	HYPH
work_knprvzmplre5lark3gt55of23e	12	16	08:00	08:00	CD
work_knprvzmplre5lark3gt55of23e	12	17	Pulmonary	pulmonary	JJ
work_knprvzmplre5lark3gt55of23e	12	18	toxicity	toxicity	NN
work_knprvzmplre5lark3gt55of23e	12	19	of	of	IN
work_knprvzmplre5lark3gt55of23e	12	20	therapy	therapy	NN
work_knprvzmplre5lark3gt55of23e	12	21	Jett	Jett	NNP
work_knprvzmplre5lark3gt55of23e	12	22	,	,	,
work_knprvzmplre5lark3gt55of23e	12	23	James	James	NNP
work_knprvzmplre5lark3gt55of23e	12	24	R.	R.	NNP
work_knprvzmplre5lark3gt55of23e	12	25	Mayo	Mayo	NNP
work_knprvzmplre5lark3gt55of23e	12	26	Clinic	Clinic	NNP
work_knprvzmplre5lark3gt55of23e	12	27	,	,	,
work_knprvzmplre5lark3gt55of23e	12	28	Rochester	Rochester	NNP
work_knprvzmplre5lark3gt55of23e	12	29	,	,	,
work_knprvzmplre5lark3gt55of23e	12	30	MN	MN	NNP
work_knprvzmplre5lark3gt55of23e	12	31	,	,	,
work_knprvzmplre5lark3gt55of23e	12	32	USA	USA	NNP
work_knprvzmplre5lark3gt55of23e	12	33	The	the	DT
work_knprvzmplre5lark3gt55of23e	12	34	toxicities	toxicity	NNS
work_knprvzmplre5lark3gt55of23e	12	35	of	of	IN
work_knprvzmplre5lark3gt55of23e	12	36	dyspnea	dyspnea	NN
work_knprvzmplre5lark3gt55of23e	12	37	,	,	,
work_knprvzmplre5lark3gt55of23e	12	38	hypoxia	hypoxia	NNP
work_knprvzmplre5lark3gt55of23e	12	39	,	,	,
work_knprvzmplre5lark3gt55of23e	12	40	pneumonitis	pneumonitis	NN
work_knprvzmplre5lark3gt55of23e	12	41	,	,	,
work_knprvzmplre5lark3gt55of23e	12	42	and/or	and/or	CC
work_knprvzmplre5lark3gt55of23e	12	43	fibrosis	fibrosis	VBP
work_knprvzmplre5lark3gt55of23e	12	44	related	related	JJ
work_knprvzmplre5lark3gt55of23e	12	45	to	to	IN
work_knprvzmplre5lark3gt55of23e	12	46	thoracic	thoracic	NNP
work_knprvzmplre5lark3gt55of23e	12	47	radiotherapy	radiotherapy	NNP
work_knprvzmplre5lark3gt55of23e	12	48	have	have	VBP
work_knprvzmplre5lark3gt55of23e	12	49	been	be	VBN
work_knprvzmplre5lark3gt55of23e	12	50	observed	observe	VBN
work_knprvzmplre5lark3gt55of23e	12	51	for	for	IN
work_knprvzmplre5lark3gt55of23e	12	52	many	many	JJ
work_knprvzmplre5lark3gt55of23e	12	53	years	year	NNS
work_knprvzmplre5lark3gt55of23e	12	54	.	.	.
work_knprvzmplre5lark3gt55of23e	13	1	Toxicities	toxicity	NNS
work_knprvzmplre5lark3gt55of23e	13	2	are	be	VBP
work_knprvzmplre5lark3gt55of23e	13	3	generally	generally	RB
work_knprvzmplre5lark3gt55of23e	13	4	graded	grade	VBN
work_knprvzmplre5lark3gt55of23e	13	5	by	by	IN
work_knprvzmplre5lark3gt55of23e	13	6	using	use	VBG
work_knprvzmplre5lark3gt55of23e	13	7	the	the	DT
work_knprvzmplre5lark3gt55of23e	13	8	NCI	NCI	NNP
work_knprvzmplre5lark3gt55of23e	13	9	Common	Common	NNP
work_knprvzmplre5lark3gt55of23e	13	10	Toxicity	Toxicity	NNP
work_knprvzmplre5lark3gt55of23e	13	11	Criteria	Criteria	NNPS
work_knprvzmplre5lark3gt55of23e	13	12	or	or	CC
work_knprvzmplre5lark3gt55of23e	13	13	the	the	DT
work_knprvzmplre5lark3gt55of23e	13	14	WHO	WHO	NNP
work_knprvzmplre5lark3gt55of23e	13	15	toxicity	toxicity	NN
work_knprvzmplre5lark3gt55of23e	13	16	criteria	criterion	NNS
work_knprvzmplre5lark3gt55of23e	13	17	(	(	-LRB-
work_knprvzmplre5lark3gt55of23e	13	18	http://www.fda.gov/cder/cancer/toxicityframe	http://www.fda.gov/cder/cancer/toxicityframe	NNP
work_knprvzmplre5lark3gt55of23e	13	19	.	.	.
work_knprvzmplre5lark3gt55of23e	14	1	htm	htm	NNP
work_knprvzmplre5lark3gt55of23e	14	2	)	)	-RRB-
work_knprvzmplre5lark3gt55of23e	14	3	.	.	.
work_knprvzmplre5lark3gt55of23e	15	1	Dose	dose	NN
work_knprvzmplre5lark3gt55of23e	15	2	-	-	HYPH
work_knprvzmplre5lark3gt55of23e	15	3	volume	volume	NN
work_knprvzmplre5lark3gt55of23e	15	4	histograms	histogram	NNS
work_knprvzmplre5lark3gt55of23e	15	5	have	have	VBP
work_knprvzmplre5lark3gt55of23e	15	6	been	be	VBN
work_knprvzmplre5lark3gt55of23e	15	7	developed	develop	VBN
work_knprvzmplre5lark3gt55of23e	15	8	to	to	TO
work_knprvzmplre5lark3gt55of23e	15	9	evaluate	evaluate	VB
work_knprvzmplre5lark3gt55of23e	15	10	the	the	DT
work_knprvzmplre5lark3gt55of23e	15	11	volume	volume	NN
work_knprvzmplre5lark3gt55of23e	15	12	of	of	IN
work_knprvzmplre5lark3gt55of23e	15	13	lung	lung	NN
work_knprvzmplre5lark3gt55of23e	15	14	receiving	receive	VBG
work_knprvzmplre5lark3gt55of23e	15	15	various	various	JJ
work_knprvzmplre5lark3gt55of23e	15	16	doses	dose	NNS
work_knprvzmplre5lark3gt55of23e	15	17	of	of	IN
work_knprvzmplre5lark3gt55of23e	15	18	radiation	radiation	NN
work_knprvzmplre5lark3gt55of23e	15	19	.	.	.
work_knprvzmplre5lark3gt55of23e	16	1	The	the	DT
work_knprvzmplre5lark3gt55of23e	16	2	V20	V20	NNP
work_knprvzmplre5lark3gt55of23e	16	3	is	be	VBZ
work_knprvzmplre5lark3gt55of23e	16	4	the	the	DT
work_knprvzmplre5lark3gt55of23e	16	5	per-	per-	JJ
work_knprvzmplre5lark3gt55of23e	16	6	centage	centage	NN
work_knprvzmplre5lark3gt55of23e	16	7	of	of	IN
work_knprvzmplre5lark3gt55of23e	16	8	lung	lung	NN
work_knprvzmplre5lark3gt55of23e	16	9	volume	volume	NN
work_knprvzmplre5lark3gt55of23e	16	10	that	that	WDT
work_knprvzmplre5lark3gt55of23e	16	11	receives	receive	VBZ
work_knprvzmplre5lark3gt55of23e	16	12	a	a	DT
work_knprvzmplre5lark3gt55of23e	16	13	radiation	radiation	NN
work_knprvzmplre5lark3gt55of23e	16	14	dose	dose	NN
work_knprvzmplre5lark3gt55of23e	16	15	of	of	IN
work_knprvzmplre5lark3gt55of23e	16	16	20	20	CD
work_knprvzmplre5lark3gt55of23e	16	17	Gy	Gy	NNS
work_knprvzmplre5lark3gt55of23e	16	18	or	or	CC
work_knprvzmplre5lark3gt55of23e	16	19	more	more	JJR
work_knprvzmplre5lark3gt55of23e	16	20	.	.	.
work_knprvzmplre5lark3gt55of23e	17	1	In	in	IN
work_knprvzmplre5lark3gt55of23e	17	2	general	general	JJ
work_knprvzmplre5lark3gt55of23e	17	3	,	,	,
work_knprvzmplre5lark3gt55of23e	17	4	the	the	DT
work_knprvzmplre5lark3gt55of23e	17	5	larger	large	JJR
work_knprvzmplre5lark3gt55of23e	17	6	the	the	DT
work_knprvzmplre5lark3gt55of23e	17	7	V20	V20	NNP
work_knprvzmplre5lark3gt55of23e	17	8	volume	volume	NN
work_knprvzmplre5lark3gt55of23e	17	9	,	,	,
work_knprvzmplre5lark3gt55of23e	17	10	the	the	DT
work_knprvzmplre5lark3gt55of23e	17	11	higher	high	JJR
work_knprvzmplre5lark3gt55of23e	17	12	the	the	DT
work_knprvzmplre5lark3gt55of23e	17	13	risk	risk	NN
work_knprvzmplre5lark3gt55of23e	17	14	of	of	IN
work_knprvzmplre5lark3gt55of23e	17	15	radiation	radiation	NN
work_knprvzmplre5lark3gt55of23e	17	16	pneumonitis	pneumonitis	VB
work_knprvzmplre5lark3gt55of23e	17	17	,	,	,
work_knprvzmplre5lark3gt55of23e	17	18	and	and	CC
work_knprvzmplre5lark3gt55of23e	17	19	V20	V20	NNP
work_knprvzmplre5lark3gt55of23e	17	20	volume	volume	NN
work_knprvzmplre5lark3gt55of23e	17	21	of	of	IN
work_knprvzmplre5lark3gt55of23e	17	22	35	35	CD
work_knprvzmplre5lark3gt55of23e	17	23	%	%	NN
work_knprvzmplre5lark3gt55of23e	17	24	or	or	CC
work_knprvzmplre5lark3gt55of23e	17	25	more	more	JJR
work_knprvzmplre5lark3gt55of23e	17	26	are	be	VBP
work_knprvzmplre5lark3gt55of23e	17	27	associated	associate	VBN
work_knprvzmplre5lark3gt55of23e	17	28	with	with	IN
work_knprvzmplre5lark3gt55of23e	17	29	high	high	JJ
work_knprvzmplre5lark3gt55of23e	17	30	risk	risk	NN
work_knprvzmplre5lark3gt55of23e	17	31	of	of	IN
work_knprvzmplre5lark3gt55of23e	17	32	acute	acute	JJ
work_knprvzmplre5lark3gt55of23e	17	33	radiation	radiation	NN
work_knprvzmplre5lark3gt55of23e	17	34	pneumonitis	pneumonitis	NN
work_knprvzmplre5lark3gt55of23e	17	35	and	and	CC
work_knprvzmplre5lark3gt55of23e	17	36	late	late	JJ
work_knprvzmplre5lark3gt55of23e	17	37	scarring	scarring	NN
work_knprvzmplre5lark3gt55of23e	17	38	(	(	-LRB-
work_knprvzmplre5lark3gt55of23e	17	39	1	1	CD
work_knprvzmplre5lark3gt55of23e	17	40	)	)	-RRB-
work_knprvzmplre5lark3gt55of23e	17	41	.	.	.
work_knprvzmplre5lark3gt55of23e	18	1	Acute	acute	JJ
work_knprvzmplre5lark3gt55of23e	18	2	radia-	radia-	NN
work_knprvzmplre5lark3gt55of23e	18	3	tion	tion	NN
work_knprvzmplre5lark3gt55of23e	18	4	pneumonitis	pneumonitis	NN
work_knprvzmplre5lark3gt55of23e	18	5	occurs	occur	VBZ
work_knprvzmplre5lark3gt55of23e	18	6	within	within	IN
work_knprvzmplre5lark3gt55of23e	18	7	1	1	CD
work_knprvzmplre5lark3gt55of23e	18	8	-	-	SYM
work_knprvzmplre5lark3gt55of23e	18	9	3	3	CD
work_knprvzmplre5lark3gt55of23e	18	10	months	month	NNS
work_knprvzmplre5lark3gt55of23e	18	11	of	of	IN
work_knprvzmplre5lark3gt55of23e	18	12	radiotherapy	radiotherapy	NN
work_knprvzmplre5lark3gt55of23e	18	13	,	,	,
work_knprvzmplre5lark3gt55of23e	18	14	and	and	CC
work_knprvzmplre5lark3gt55of23e	18	15	may	may	MD
work_knprvzmplre5lark3gt55of23e	18	16	develop	develop	VB
work_knprvzmplre5lark3gt55of23e	18	17	in	in	IN
work_knprvzmplre5lark3gt55of23e	18	18	5	5	CD
work_knprvzmplre5lark3gt55of23e	18	19	-	-	SYM
work_knprvzmplre5lark3gt55of23e	18	20	15	15	CD
work_knprvzmplre5lark3gt55of23e	18	21	%	%	NN
work_knprvzmplre5lark3gt55of23e	18	22	of	of	IN
work_knprvzmplre5lark3gt55of23e	18	23	patients	patient	NNS
work_knprvzmplre5lark3gt55of23e	18	24	.	.	.
work_knprvzmplre5lark3gt55of23e	19	1	Direct	direct	JJ
work_knprvzmplre5lark3gt55of23e	19	2	injury	injury	NN
work_knprvzmplre5lark3gt55of23e	19	3	to	to	IN
work_knprvzmplre5lark3gt55of23e	19	4	endothelial	endothelial	JJ
work_knprvzmplre5lark3gt55of23e	19	5	and	and	CC
work_knprvzmplre5lark3gt55of23e	19	6	epithelial	epithelial	JJ
work_knprvzmplre5lark3gt55of23e	19	7	cells	cell	NNS
work_knprvzmplre5lark3gt55of23e	19	8	may	may	MD
work_knprvzmplre5lark3gt55of23e	19	9	result	result	VB
work_knprvzmplre5lark3gt55of23e	19	10	in	in	IN
work_knprvzmplre5lark3gt55of23e	19	11	radiographic	radiographic	JJ
work_knprvzmplre5lark3gt55of23e	19	12	findings	finding	NNS
work_knprvzmplre5lark3gt55of23e	19	13	of	of	IN
work_knprvzmplre5lark3gt55of23e	19	14	pulmonary	pulmonary	JJ
work_knprvzmplre5lark3gt55of23e	19	15	infiltrates	infiltrate	NNS
work_knprvzmplre5lark3gt55of23e	19	16	in	in	IN
work_knprvzmplre5lark3gt55of23e	19	17	the	the	DT
work_knprvzmplre5lark3gt55of23e	19	18	field	field	NN
work_knprvzmplre5lark3gt55of23e	19	19	of	of	IN
work_knprvzmplre5lark3gt55of23e	19	20	radiation	radiation	NN
work_knprvzmplre5lark3gt55of23e	19	21	,	,	,
work_knprvzmplre5lark3gt55of23e	19	22	but	but	CC
work_knprvzmplre5lark3gt55of23e	19	23	also	also	RB
work_knprvzmplre5lark3gt55of23e	19	24	“	"	``
work_knprvzmplre5lark3gt55of23e	19	25	out	out	IN
work_knprvzmplre5lark3gt55of23e	19	26	of	of	IN
work_knprvzmplre5lark3gt55of23e	19	27	field	field	NN
work_knprvzmplre5lark3gt55of23e	19	28	”	"	''
work_knprvzmplre5lark3gt55of23e	19	29	responses	response	NNS
work_knprvzmplre5lark3gt55of23e	19	30	have	have	VBP
work_knprvzmplre5lark3gt55of23e	19	31	been	be	VBN
work_knprvzmplre5lark3gt55of23e	19	32	described	describe	VBN
work_knprvzmplre5lark3gt55of23e	19	33	and	and	CC
work_knprvzmplre5lark3gt55of23e	19	34	biopsies	biopsy	NNS
work_knprvzmplre5lark3gt55of23e	19	35	demonstrate	demonstrate	VBP
work_knprvzmplre5lark3gt55of23e	19	36	a	a	DT
work_knprvzmplre5lark3gt55of23e	19	37	bronchiolitis	bronchiolitis	NN
work_knprvzmplre5lark3gt55of23e	19	38	obliterans	obliterans	NNPS
work_knprvzmplre5lark3gt55of23e	19	39	organizing	organize	VBG
work_knprvzmplre5lark3gt55of23e	19	40	pneumo-	pneumo-	NN
work_knprvzmplre5lark3gt55of23e	19	41	nitis	nitis	NN
work_knprvzmplre5lark3gt55of23e	19	42	(	(	-LRB-
work_knprvzmplre5lark3gt55of23e	19	43	BOOP	BOOP	NNP
work_knprvzmplre5lark3gt55of23e	19	44	)	)	-RRB-
work_knprvzmplre5lark3gt55of23e	19	45	like	like	IN
work_knprvzmplre5lark3gt55of23e	19	46	reaction	reaction	NN
work_knprvzmplre5lark3gt55of23e	19	47	(	(	-LRB-
work_knprvzmplre5lark3gt55of23e	19	48	also	also	RB
work_knprvzmplre5lark3gt55of23e	19	49	called	call	VBN
work_knprvzmplre5lark3gt55of23e	19	50	cryptogenic	cryptogenic	JJ
work_knprvzmplre5lark3gt55of23e	19	51	organizing	organizing	NN
work_knprvzmplre5lark3gt55of23e	19	52	pneumo-	pneumo-	NNP
work_knprvzmplre5lark3gt55of23e	19	53	nia	nia	NNP
work_knprvzmplre5lark3gt55of23e	19	54	–	–	:
work_knprvzmplre5lark3gt55of23e	19	55	COP	COP	NNP
work_knprvzmplre5lark3gt55of23e	19	56	)	)	-RRB-
work_knprvzmplre5lark3gt55of23e	19	57	.	.	.
work_knprvzmplre5lark3gt55of23e	20	1	The	the	DT
work_knprvzmplre5lark3gt55of23e	20	2	RTOG	rtog	NN
work_knprvzmplre5lark3gt55of23e	20	3	evaluated	evaluate	VBD
work_knprvzmplre5lark3gt55of23e	20	4	acute	acute	JJ
work_knprvzmplre5lark3gt55of23e	20	5	and	and	CC
work_knprvzmplre5lark3gt55of23e	20	6	late	late	JJ
work_knprvzmplre5lark3gt55of23e	20	7	(	(	-LRB-
work_knprvzmplre5lark3gt55of23e	20	8	90	90	CD
work_knprvzmplre5lark3gt55of23e	20	9	days	day	NNS
work_knprvzmplre5lark3gt55of23e	20	10	from	from	IN
work_knprvzmplre5lark3gt55of23e	20	11	start	start	NN
work_knprvzmplre5lark3gt55of23e	20	12	of	of	IN
work_knprvzmplre5lark3gt55of23e	20	13	RT	RT	NNP
work_knprvzmplre5lark3gt55of23e	20	14	)	)	-RRB-
work_knprvzmplre5lark3gt55of23e	20	15	pulmonary	pulmonary	JJ
work_knprvzmplre5lark3gt55of23e	20	16	toxicities	toxicity	NNS
work_knprvzmplre5lark3gt55of23e	20	17	associated	associate	VBN
work_knprvzmplre5lark3gt55of23e	20	18	with	with	IN
work_knprvzmplre5lark3gt55of23e	20	19	5	5	CD
work_knprvzmplre5lark3gt55of23e	20	20	completed	complete	VBN
work_knprvzmplre5lark3gt55of23e	20	21	trials	trial	NNS
work_knprvzmplre5lark3gt55of23e	20	22	of	of	IN
work_knprvzmplre5lark3gt55of23e	20	23	thoracic	thoracic	NNP
work_knprvzmplre5lark3gt55of23e	20	24	radiotherapy	radiotherapy	NNP
work_knprvzmplre5lark3gt55of23e	20	25	with	with	IN
work_knprvzmplre5lark3gt55of23e	20	26	sequential	sequential	JJ
work_knprvzmplre5lark3gt55of23e	20	27	or	or	CC
work_knprvzmplre5lark3gt55of23e	20	28	concurrent	concurrent	JJ
work_knprvzmplre5lark3gt55of23e	20	29	chemotherapy	chemotherapy	NN
work_knprvzmplre5lark3gt55of23e	20	30	(	(	-LRB-
work_knprvzmplre5lark3gt55of23e	20	31	2	2	CD
work_knprvzmplre5lark3gt55of23e	20	32	)	)	-RRB-
work_knprvzmplre5lark3gt55of23e	20	33	.	.	.
work_knprvzmplre5lark3gt55of23e	21	1	Acute	acute	JJ
work_knprvzmplre5lark3gt55of23e	21	2	pulmonary	pulmonary	JJ
work_knprvzmplre5lark3gt55of23e	21	3	toxicity	toxicity	NN
work_knprvzmplre5lark3gt55of23e	21	4	of	of	IN
work_knprvzmplre5lark3gt55of23e	21	5	grade	grade	NN
work_knprvzmplre5lark3gt55of23e	21	6	3	3	CD
work_knprvzmplre5lark3gt55of23e	21	7	or	or	CC
work_knprvzmplre5lark3gt55of23e	21	8	greater	great	JJR
work_knprvzmplre5lark3gt55of23e	21	9	occurred	occur	VBD
work_knprvzmplre5lark3gt55of23e	21	10	in	in	IN
work_knprvzmplre5lark3gt55of23e	21	11	4	4	CD
work_knprvzmplre5lark3gt55of23e	21	12	-	-	SYM
work_knprvzmplre5lark3gt55of23e	21	13	7	7	CD
work_knprvzmplre5lark3gt55of23e	21	14	%	%	NN
work_knprvzmplre5lark3gt55of23e	21	15	of	of	IN
work_knprvzmplre5lark3gt55of23e	21	16	partici-	partici-	NN
work_knprvzmplre5lark3gt55of23e	21	17	pants	pant	NNS
work_knprvzmplre5lark3gt55of23e	21	18	.	.	.
work_knprvzmplre5lark3gt55of23e	22	1	Late	late	JJ
work_knprvzmplre5lark3gt55of23e	22	2	pulmonary	pulmonary	JJ
work_knprvzmplre5lark3gt55of23e	22	3	toxicities	toxicity	NNS
work_knprvzmplre5lark3gt55of23e	22	4	occurred	occur	VBD
work_knprvzmplre5lark3gt55of23e	22	5	in	in	IN
work_knprvzmplre5lark3gt55of23e	22	6	10	10	CD
work_knprvzmplre5lark3gt55of23e	22	7	-	-	SYM
work_knprvzmplre5lark3gt55of23e	22	8	21	21	CD
work_knprvzmplre5lark3gt55of23e	22	9	%	%	NN
work_knprvzmplre5lark3gt55of23e	22	10	of	of	IN
work_knprvzmplre5lark3gt55of23e	22	11	patients	patient	NNS
work_knprvzmplre5lark3gt55of23e	22	12	.	.	.
work_knprvzmplre5lark3gt55of23e	23	1	Severe	severe	JJ
work_knprvzmplre5lark3gt55of23e	23	2	late	late	JJ
work_knprvzmplre5lark3gt55of23e	23	3	lung	lung	NN
work_knprvzmplre5lark3gt55of23e	23	4	toxicity	toxicity	NN
work_knprvzmplre5lark3gt55of23e	23	5	was	be	VBD
work_knprvzmplre5lark3gt55of23e	23	6	greater	great	JJR
work_knprvzmplre5lark3gt55of23e	23	7	in	in	IN
work_knprvzmplre5lark3gt55of23e	23	8	trials	trial	NNS
work_knprvzmplre5lark3gt55of23e	23	9	with	with	IN
work_knprvzmplre5lark3gt55of23e	23	10	concurrent	concurrent	JJ
work_knprvzmplre5lark3gt55of23e	23	11	chemotherapy	chemotherapy	NN
work_knprvzmplre5lark3gt55of23e	23	12	and	and	CC
work_knprvzmplre5lark3gt55of23e	23	13	hyperfractionated	hyperfractionate	VBN
work_knprvzmplre5lark3gt55of23e	23	14	RT	RT	NNP
work_knprvzmplre5lark3gt55of23e	23	15	,	,	,
work_knprvzmplre5lark3gt55of23e	23	16	as	as	RB
work_knprvzmplre5lark3gt55of23e	23	17	well	well	RB
work_knprvzmplre5lark3gt55of23e	23	18	as	as	IN
work_knprvzmplre5lark3gt55of23e	23	19	induction	induction	NN
work_knprvzmplre5lark3gt55of23e	23	20	chemotherapy	chemotherapy	NN
work_knprvzmplre5lark3gt55of23e	23	21	followed	follow	VBN
work_knprvzmplre5lark3gt55of23e	23	22	by	by	IN
work_knprvzmplre5lark3gt55of23e	23	23	concurrent	concurrent	JJ
work_knprvzmplre5lark3gt55of23e	23	24	chemoradiotherapy	chemoradiotherapy	NNP
work_knprvzmplre5lark3gt55of23e	23	25	(	(	-LRB-
work_knprvzmplre5lark3gt55of23e	23	26	one	one	CD
work_knprvzmplre5lark3gt55of23e	23	27	daily	daily	RB
work_knprvzmplre5lark3gt55of23e	23	28	)	)	-RRB-
work_knprvzmplre5lark3gt55of23e	23	29	.	.	.
work_knprvzmplre5lark3gt55of23e	24	1	Sequential	sequential	JJ
work_knprvzmplre5lark3gt55of23e	24	2	chemotherapy	chemotherapy	NN
work_knprvzmplre5lark3gt55of23e	24	3	and	and	CC
work_knprvzmplre5lark3gt55of23e	24	4	radiotherapy	radiotherapy	NN
work_knprvzmplre5lark3gt55of23e	24	5	had	have	VBD
work_knprvzmplre5lark3gt55of23e	24	6	lower	low	JJR
work_knprvzmplre5lark3gt55of23e	24	7	rates	rate	NNS
work_knprvzmplre5lark3gt55of23e	24	8	of	of	IN
work_knprvzmplre5lark3gt55of23e	24	9	late	late	JJ
work_knprvzmplre5lark3gt55of23e	24	10	pulmonary	pulmonary	JJ
work_knprvzmplre5lark3gt55of23e	24	11	toxicity	toxicity	NN
work_knprvzmplre5lark3gt55of23e	24	12	(	(	-LRB-
work_knprvzmplre5lark3gt55of23e	24	13	10	10	CD
work_knprvzmplre5lark3gt55of23e	24	14	%	%	NN
work_knprvzmplre5lark3gt55of23e	24	15	)	)	-RRB-
work_knprvzmplre5lark3gt55of23e	24	16	.	.	.
work_knprvzmplre5lark3gt55of23e	25	1	Ste-	Ste-	NNP
work_knprvzmplre5lark3gt55of23e	25	2	reotactic	reotactic	JJ
work_knprvzmplre5lark3gt55of23e	25	3	body	body	NN
work_knprvzmplre5lark3gt55of23e	25	4	radiation	radiation	NN
work_knprvzmplre5lark3gt55of23e	25	5	therapy	therapy	NN
work_knprvzmplre5lark3gt55of23e	25	6	(	(	-LRB-
work_knprvzmplre5lark3gt55of23e	25	7	SBRT	SBRT	NNP
work_knprvzmplre5lark3gt55of23e	25	8	)	)	-RRB-
work_knprvzmplre5lark3gt55of23e	25	9	is	be	VBZ
work_knprvzmplre5lark3gt55of23e	25	10	being	be	VBG
work_knprvzmplre5lark3gt55of23e	25	11	utilized	utilize	VBN
work_knprvzmplre5lark3gt55of23e	25	12	with	with	IN
work_knprvzmplre5lark3gt55of23e	25	13	increas-	increas-	XX
work_knprvzmplre5lark3gt55of23e	25	14	ing	ing	NN
work_knprvzmplre5lark3gt55of23e	25	15	frequency	frequency	NN
work_knprvzmplre5lark3gt55of23e	25	16	,	,	,
work_knprvzmplre5lark3gt55of23e	25	17	especially	especially	RB
work_knprvzmplre5lark3gt55of23e	25	18	for	for	IN
work_knprvzmplre5lark3gt55of23e	25	19	medically	medically	RB
work_knprvzmplre5lark3gt55of23e	25	20	inoperable	inoperable	JJ
work_knprvzmplre5lark3gt55of23e	25	21	lung	lung	NN
work_knprvzmplre5lark3gt55of23e	25	22	cancer	cancer	NN
work_knprvzmplre5lark3gt55of23e	25	23	patients	patient	NNS
work_knprvzmplre5lark3gt55of23e	25	24	.	.	.
work_knprvzmplre5lark3gt55of23e	26	1	With	with	IN
work_knprvzmplre5lark3gt55of23e	26	2	this	this	DT
work_knprvzmplre5lark3gt55of23e	26	3	technology	technology	NN
work_knprvzmplre5lark3gt55of23e	26	4	,	,	,
work_knprvzmplre5lark3gt55of23e	26	5	large	large	JJ
work_knprvzmplre5lark3gt55of23e	26	6	dose	dose	NN
work_knprvzmplre5lark3gt55of23e	26	7	fractions	fraction	NNS
work_knprvzmplre5lark3gt55of23e	26	8	are	be	VBP
work_knprvzmplre5lark3gt55of23e	26	9	given	give	VBN
work_knprvzmplre5lark3gt55of23e	26	10	to	to	IN
work_knprvzmplre5lark3gt55of23e	26	11	very	very	RB
work_knprvzmplre5lark3gt55of23e	26	12	localized	localize	VBN
work_knprvzmplre5lark3gt55of23e	26	13	fields	field	NNS
work_knprvzmplre5lark3gt55of23e	26	14	.	.	.
work_knprvzmplre5lark3gt55of23e	27	1	In	in	IN
work_knprvzmplre5lark3gt55of23e	27	2	a	a	DT
work_knprvzmplre5lark3gt55of23e	27	3	phase	phase	NN
work_knprvzmplre5lark3gt55of23e	27	4	II	II	NNP
work_knprvzmplre5lark3gt55of23e	27	5	trial	trial	NN
work_knprvzmplre5lark3gt55of23e	27	6	of	of	IN
work_knprvzmplre5lark3gt55of23e	27	7	SBRT	SBRT	NNP
work_knprvzmplre5lark3gt55of23e	27	8	,	,	,
work_knprvzmplre5lark3gt55of23e	27	9	investigators	investigator	NNS
work_knprvzmplre5lark3gt55of23e	27	10	administered	administer	VBD
work_knprvzmplre5lark3gt55of23e	27	11	60	60	CD
work_knprvzmplre5lark3gt55of23e	27	12	-	-	SYM
work_knprvzmplre5lark3gt55of23e	27	13	66	66	CD
work_knprvzmplre5lark3gt55of23e	27	14	Gy	Gy	NNP
work_knprvzmplre5lark3gt55of23e	27	15	in	in	IN
work_knprvzmplre5lark3gt55of23e	27	16	3	3	CD
work_knprvzmplre5lark3gt55of23e	27	17	fractions	fraction	NNS
work_knprvzmplre5lark3gt55of23e	27	18	over	over	IN
work_knprvzmplre5lark3gt55of23e	27	19	1	1	CD
work_knprvzmplre5lark3gt55of23e	27	20	-	-	SYM
work_knprvzmplre5lark3gt55of23e	27	21	2	2	CD
work_knprvzmplre5lark3gt55of23e	27	22	weeks	week	NNS
work_knprvzmplre5lark3gt55of23e	27	23	(	(	-LRB-
work_knprvzmplre5lark3gt55of23e	27	24	3	3	CD
work_knprvzmplre5lark3gt55of23e	27	25	)	)	-RRB-
work_knprvzmplre5lark3gt55of23e	27	26	.	.	.
work_knprvzmplre5lark3gt55of23e	28	1	Grade	Grade	NNP
work_knprvzmplre5lark3gt55of23e	28	2	3	3	CD
work_knprvzmplre5lark3gt55of23e	28	3	-	-	SYM
work_knprvzmplre5lark3gt55of23e	28	4	5	5	CD
work_knprvzmplre5lark3gt55of23e	28	5	toxicity	toxicity	NN
work_knprvzmplre5lark3gt55of23e	28	6	occurred	occur	VBD
work_knprvzmplre5lark3gt55of23e	28	7	in	in	IN
work_knprvzmplre5lark3gt55of23e	28	8	14	14	CD
work_knprvzmplre5lark3gt55of23e	28	9	of	of	IN
work_knprvzmplre5lark3gt55of23e	28	10	70	70	CD
work_knprvzmplre5lark3gt55of23e	28	11	patients	patient	NNS
work_knprvzmplre5lark3gt55of23e	28	12	enrolled	enrol	VBN
work_knprvzmplre5lark3gt55of23e	28	13	.	.	.
work_knprvzmplre5lark3gt55of23e	29	1	Toxicity	toxicity	NN
work_knprvzmplre5lark3gt55of23e	29	2	was	be	VBD
work_knprvzmplre5lark3gt55of23e	29	3	greater	great	JJR
work_knprvzmplre5lark3gt55of23e	29	4	with	with	IN
work_knprvzmplre5lark3gt55of23e	29	5	centrally	centrally	RB
work_knprvzmplre5lark3gt55of23e	29	6	located	locate	VBN
work_knprvzmplre5lark3gt55of23e	29	7	tumors	tumor	NNS
work_knprvzmplre5lark3gt55of23e	29	8	as	as	IN
work_knprvzmplre5lark3gt55of23e	29	9	compared	compare	VBN
work_knprvzmplre5lark3gt55of23e	29	10	to	to	IN
work_knprvzmplre5lark3gt55of23e	29	11	the	the	DT
work_knprvzmplre5lark3gt55of23e	29	12	peripheral	peripheral	JJ
work_knprvzmplre5lark3gt55of23e	29	13	cancers	cancer	NNS
work_knprvzmplre5lark3gt55of23e	29	14	.	.	.
work_knprvzmplre5lark3gt55of23e	30	1	There	there	EX
work_knprvzmplre5lark3gt55of23e	30	2	were	be	VBD
work_knprvzmplre5lark3gt55of23e	30	3	6	6	CD
work_knprvzmplre5lark3gt55of23e	30	4	treatment	treatment	NN
work_knprvzmplre5lark3gt55of23e	30	5	related	relate	VBN
work_knprvzmplre5lark3gt55of23e	30	6	deaths	death	NNS
work_knprvzmplre5lark3gt55of23e	30	7	.	.	.
work_knprvzmplre5lark3gt55of23e	31	1	Four	four	CD
work_knprvzmplre5lark3gt55of23e	31	2	of	of	IN
work_knprvzmplre5lark3gt55of23e	31	3	these	these	DT
work_knprvzmplre5lark3gt55of23e	31	4	deaths	death	NNS
work_knprvzmplre5lark3gt55of23e	31	5	were	be	VBD
work_knprvzmplre5lark3gt55of23e	31	6	associated	associate	VBN
work_knprvzmplre5lark3gt55of23e	31	7	with	with	IN
work_knprvzmplre5lark3gt55of23e	31	8	pneumonia	pneumonia	NN
work_knprvzmplre5lark3gt55of23e	31	9	.	.	.
work_knprvzmplre5lark3gt55of23e	32	1	This	this	DT
work_knprvzmplre5lark3gt55of23e	32	2	increased	increase	VBN
work_knprvzmplre5lark3gt55of23e	32	3	toxicity	toxicity	NN
work_knprvzmplre5lark3gt55of23e	32	4	with	with	IN
work_knprvzmplre5lark3gt55of23e	32	5	centrally	centrally	RB
work_knprvzmplre5lark3gt55of23e	32	6	located	locate	VBN
work_knprvzmplre5lark3gt55of23e	32	7	tumors	tumor	NNS
work_knprvzmplre5lark3gt55of23e	32	8	is	be	VBZ
work_knprvzmplre5lark3gt55of23e	32	9	due	due	JJ
work_knprvzmplre5lark3gt55of23e	32	10	to	to	IN
work_knprvzmplre5lark3gt55of23e	32	11	bronchial	bronchial	JJ
work_knprvzmplre5lark3gt55of23e	32	12	stenosis	stenosis	NN
work_knprvzmplre5lark3gt55of23e	32	13	and	and	CC
work_knprvzmplre5lark3gt55of23e	32	14	scarring	scar	VBG
work_knprvzmplre5lark3gt55of23e	32	15	due	due	IN
work_knprvzmplre5lark3gt55of23e	32	16	to	to	IN
work_knprvzmplre5lark3gt55of23e	32	17	the	the	DT
work_knprvzmplre5lark3gt55of23e	32	18	high	high	JJ
work_knprvzmplre5lark3gt55of23e	32	19	dose	dose	NN
work_knprvzmplre5lark3gt55of23e	32	20	of	of	IN
work_knprvzmplre5lark3gt55of23e	32	21	radiation	radiation	NN
work_knprvzmplre5lark3gt55of23e	32	22	.	.	.
work_knprvzmplre5lark3gt55of23e	33	1	Gemcitabine	Gemcitabine	NNP
work_knprvzmplre5lark3gt55of23e	33	2	Gemcitabine	Gemcitabine	NNP
work_knprvzmplre5lark3gt55of23e	33	3	pulmonary	pulmonary	JJ
work_knprvzmplre5lark3gt55of23e	33	4	toxicity	toxicity	NN
work_knprvzmplre5lark3gt55of23e	33	5	has	have	VBZ
work_knprvzmplre5lark3gt55of23e	33	6	been	be	VBN
work_knprvzmplre5lark3gt55of23e	33	7	reported	report	VBN
work_knprvzmplre5lark3gt55of23e	33	8	in	in	IN
work_knprvzmplre5lark3gt55of23e	33	9	1	1	CD
work_knprvzmplre5lark3gt55of23e	33	10	-	-	SYM
work_knprvzmplre5lark3gt55of23e	33	11	3	3	CD
work_knprvzmplre5lark3gt55of23e	33	12	%	%	NN
work_knprvzmplre5lark3gt55of23e	33	13	of	of	IN
work_knprvzmplre5lark3gt55of23e	33	14	patients	patient	NNS
work_knprvzmplre5lark3gt55of23e	33	15	treated	treat	VBN
work_knprvzmplre5lark3gt55of23e	33	16	with	with	IN
work_knprvzmplre5lark3gt55of23e	33	17	this	this	DT
work_knprvzmplre5lark3gt55of23e	33	18	agent	agent	NN
work_knprvzmplre5lark3gt55of23e	33	19	and	and	CC
work_knprvzmplre5lark3gt55of23e	33	20	may	may	MD
work_knprvzmplre5lark3gt55of23e	33	21	be	be	VB
work_knprvzmplre5lark3gt55of23e	33	22	fatal	fatal	JJ
work_knprvzmplre5lark3gt55of23e	33	23	.	.	.
work_knprvzmplre5lark3gt55of23e	34	1	The	the	DT
work_knprvzmplre5lark3gt55of23e	34	2	CT	CT	NNP
work_knprvzmplre5lark3gt55of23e	34	3	features	feature	NNS
work_knprvzmplre5lark3gt55of23e	34	4	include	include	VBP
work_knprvzmplre5lark3gt55of23e	34	5	ground	ground	NN
work_knprvzmplre5lark3gt55of23e	34	6	-	-	HYPH
work_knprvzmplre5lark3gt55of23e	34	7	glass	glass	NN
work_knprvzmplre5lark3gt55of23e	34	8	opacities	opacity	NNS
work_knprvzmplre5lark3gt55of23e	34	9	,	,	,
work_knprvzmplre5lark3gt55of23e	34	10	thickened	thicken	VBD
work_knprvzmplre5lark3gt55of23e	34	11	septal	septal	JJ
work_knprvzmplre5lark3gt55of23e	34	12	lines	line	NNS
work_knprvzmplre5lark3gt55of23e	34	13	and	and	CC
work_knprvzmplre5lark3gt55of23e	34	14	reticular	reticular	JJ
work_knprvzmplre5lark3gt55of23e	34	15	opaci-	opaci-	JJ
work_knprvzmplre5lark3gt55of23e	34	16	ties	tie	NNS
work_knprvzmplre5lark3gt55of23e	34	17	.	.	.
work_knprvzmplre5lark3gt55of23e	35	1	The	the	DT
work_knprvzmplre5lark3gt55of23e	35	2	distribution	distribution	NN
work_knprvzmplre5lark3gt55of23e	35	3	is	be	VBZ
work_knprvzmplre5lark3gt55of23e	35	4	diffuse	diffuse	NN
work_knprvzmplre5lark3gt55of23e	35	5	and	and	CC
work_knprvzmplre5lark3gt55of23e	35	6	bilateral	bilateral	JJ
work_knprvzmplre5lark3gt55of23e	35	7	.	.	.
work_knprvzmplre5lark3gt55of23e	36	1	Gemcitabine	gemcitabine	JJ
work_knprvzmplre5lark3gt55of23e	36	2	pulmonary	pulmonary	JJ
work_knprvzmplre5lark3gt55of23e	36	3	toxicity	toxicity	NN
work_knprvzmplre5lark3gt55of23e	36	4	may	may	MD
work_knprvzmplre5lark3gt55of23e	36	5	be	be	VB
work_knprvzmplre5lark3gt55of23e	36	6	difficult	difficult	JJ
work_knprvzmplre5lark3gt55of23e	36	7	to	to	TO
work_knprvzmplre5lark3gt55of23e	36	8	differentiate	differentiate	VB
work_knprvzmplre5lark3gt55of23e	36	9	from	from	IN
work_knprvzmplre5lark3gt55of23e	36	10	viral	viral	JJ
work_knprvzmplre5lark3gt55of23e	36	11	pneumonitis	pneumonitis	NN
work_knprvzmplre5lark3gt55of23e	36	12	.	.	.
work_knprvzmplre5lark3gt55of23e	37	1	It	-PRON-	PRP
work_knprvzmplre5lark3gt55of23e	37	2	is	be	VBZ
work_knprvzmplre5lark3gt55of23e	37	3	important	important	JJ
work_knprvzmplre5lark3gt55of23e	37	4	to	to	TO
work_knprvzmplre5lark3gt55of23e	37	5	discontinue	discontinue	VB
work_knprvzmplre5lark3gt55of23e	37	6	treatment	treatment	NN
work_knprvzmplre5lark3gt55of23e	37	7	as	as	RB
work_knprvzmplre5lark3gt55of23e	37	8	soon	soon	RB
work_knprvzmplre5lark3gt55of23e	37	9	as	as	IN
work_knprvzmplre5lark3gt55of23e	37	10	it	-PRON-	PRP
work_knprvzmplre5lark3gt55of23e	37	11	is	be	VBZ
work_knprvzmplre5lark3gt55of23e	37	12	suspected	suspect	VBN
work_knprvzmplre5lark3gt55of23e	37	13	because	because	IN
work_knprvzmplre5lark3gt55of23e	37	14	an	an	DT
work_knprvzmplre5lark3gt55of23e	37	15	additional	additional	JJ
work_knprvzmplre5lark3gt55of23e	37	16	treatment	treatment	NN
work_knprvzmplre5lark3gt55of23e	37	17	may	may	MD
work_knprvzmplre5lark3gt55of23e	37	18	prove	prove	VB
work_knprvzmplre5lark3gt55of23e	37	19	to	to	TO
work_knprvzmplre5lark3gt55of23e	37	20	be	be	VB
work_knprvzmplre5lark3gt55of23e	37	21	fatal	fatal	JJ
work_knprvzmplre5lark3gt55of23e	37	22	.	.	.
work_knprvzmplre5lark3gt55of23e	38	1	In	in	IN
work_knprvzmplre5lark3gt55of23e	38	2	severe	severe	JJ
work_knprvzmplre5lark3gt55of23e	38	3	cases	case	NNS
work_knprvzmplre5lark3gt55of23e	38	4	,	,	,
work_knprvzmplre5lark3gt55of23e	38	5	corticoste-	corticoste-	NNP
work_knprvzmplre5lark3gt55of23e	38	6	roids	roid	NNS
work_knprvzmplre5lark3gt55of23e	38	7	are	be	VBP
work_knprvzmplre5lark3gt55of23e	38	8	usually	usually	RB
work_knprvzmplre5lark3gt55of23e	38	9	given	give	VBN
work_knprvzmplre5lark3gt55of23e	38	10	although	although	IN
work_knprvzmplre5lark3gt55of23e	38	11	their	-PRON-	PRP$
work_knprvzmplre5lark3gt55of23e	38	12	efficacy	efficacy	NN
work_knprvzmplre5lark3gt55of23e	38	13	is	be	VBZ
work_knprvzmplre5lark3gt55of23e	38	14	uncertain	uncertain	JJ
work_knprvzmplre5lark3gt55of23e	38	15	.	.	.
work_knprvzmplre5lark3gt55of23e	39	1	Gemcitabine	Gemcitabine	NNP
work_knprvzmplre5lark3gt55of23e	39	2	is	be	VBZ
work_knprvzmplre5lark3gt55of23e	39	3	a	a	DT
work_knprvzmplre5lark3gt55of23e	39	4	potent	potent	JJ
work_knprvzmplre5lark3gt55of23e	39	5	radiation	radiation	NN
work_knprvzmplre5lark3gt55of23e	39	6	sensitizer	sensitizer	NN
work_knprvzmplre5lark3gt55of23e	39	7	with	with	IN
work_knprvzmplre5lark3gt55of23e	39	8	recall	recall	NN
work_knprvzmplre5lark3gt55of23e	39	9	phenomena	phenomenon	NNS
work_knprvzmplre5lark3gt55of23e	39	10	.	.	.
work_knprvzmplre5lark3gt55of23e	40	1	The	the	DT
work_knprvzmplre5lark3gt55of23e	40	2	maximum	maximum	JJ
work_knprvzmplre5lark3gt55of23e	40	3	dose	dose	NN
work_knprvzmplre5lark3gt55of23e	40	4	of	of	IN
work_knprvzmplre5lark3gt55of23e	40	5	gemcitabine	gemcitabine	JJ
work_knprvzmplre5lark3gt55of23e	40	6	given	give	VBN
work_knprvzmplre5lark3gt55of23e	40	7	with	with	IN
work_knprvzmplre5lark3gt55of23e	40	8	concurrent	concurrent	JJ
work_knprvzmplre5lark3gt55of23e	40	9	thoracic	thoracic	NNP
work_knprvzmplre5lark3gt55of23e	40	10	radiotherapy	radiotherapy	NN
work_knprvzmplre5lark3gt55of23e	40	11	is	be	VBZ
work_knprvzmplre5lark3gt55of23e	40	12	substantially	substantially	RB
work_knprvzmplre5lark3gt55of23e	40	13	attenuated	attenuate	VBN
work_knprvzmplre5lark3gt55of23e	40	14	,	,	,
work_knprvzmplre5lark3gt55of23e	40	15	from	from	IN
work_knprvzmplre5lark3gt55of23e	40	16	the	the	DT
work_knprvzmplre5lark3gt55of23e	40	17	usual	usual	JJ
work_knprvzmplre5lark3gt55of23e	40	18	doses	dose	NNS
work_knprvzmplre5lark3gt55of23e	40	19	when	when	WRB
work_knprvzmplre5lark3gt55of23e	40	20	given	give	VBN
work_knprvzmplre5lark3gt55of23e	40	21	alone	alone	RB
work_knprvzmplre5lark3gt55of23e	40	22	,	,	,
work_knprvzmplre5lark3gt55of23e	40	23	because	because	IN
work_knprvzmplre5lark3gt55of23e	40	24	of	of	IN
work_knprvzmplre5lark3gt55of23e	40	25	the	the	DT
work_knprvzmplre5lark3gt55of23e	40	26	risk	risk	NN
work_knprvzmplre5lark3gt55of23e	40	27	of	of	IN
work_knprvzmplre5lark3gt55of23e	40	28	pneumonitis	pneumonitis	NN
work_knprvzmplre5lark3gt55of23e	40	29	.	.	.
work_knprvzmplre5lark3gt55of23e	41	1	In	in	IN
work_knprvzmplre5lark3gt55of23e	41	2	a	a	DT
work_knprvzmplre5lark3gt55of23e	41	3	phase	phase	NN
work_knprvzmplre5lark3gt55of23e	41	4	I	-PRON-	PRP
work_knprvzmplre5lark3gt55of23e	41	5	trial	trial	NN
work_knprvzmplre5lark3gt55of23e	41	6	of	of	IN
work_knprvzmplre5lark3gt55of23e	41	7	the	the	DT
work_knprvzmplre5lark3gt55of23e	41	8	CALGB	CALGB	NNP
work_knprvzmplre5lark3gt55of23e	41	9	,	,	,
work_knprvzmplre5lark3gt55of23e	41	10	the	the	DT
work_knprvzmplre5lark3gt55of23e	41	11	maximum	maximum	NN
work_knprvzmplre5lark3gt55of23e	41	12	tolerated	tolerate	VBN
work_knprvzmplre5lark3gt55of23e	41	13	dose	dose	NN
work_knprvzmplre5lark3gt55of23e	41	14	of	of	IN
work_knprvzmplre5lark3gt55of23e	41	15	twice	twice	RB
work_knprvzmplre5lark3gt55of23e	41	16	weekly	weekly	JJ
work_knprvzmplre5lark3gt55of23e	41	17	gemcitabine	gemcitabine	NNP
work_knprvzmplre5lark3gt55of23e	41	18	was	be	VBD
work_knprvzmplre5lark3gt55of23e	41	19	35	35	CD
work_knprvzmplre5lark3gt55of23e	41	20	mg	mg	NNP
work_knprvzmplre5lark3gt55of23e	41	21	/	/	SYM
work_knprvzmplre5lark3gt55of23e	41	22	m2	m2	NNP
work_knprvzmplre5lark3gt55of23e	41	23	(	(	-LRB-
work_knprvzmplre5lark3gt55of23e	41	24	70	70	CD
work_knprvzmplre5lark3gt55of23e	41	25	mg	mg	NNP
work_knprvzmplre5lark3gt55of23e	41	26	/	/	SYM
work_knprvzmplre5lark3gt55of23e	41	27	m2	m2	NNP
work_knprvzmplre5lark3gt55of23e	41	28	/	/	SYM
work_knprvzmplre5lark3gt55of23e	41	29	week	week	NN
work_knprvzmplre5lark3gt55of23e	41	30	)	)	-RRB-
work_knprvzmplre5lark3gt55of23e	41	31	given	give	VBN
work_knprvzmplre5lark3gt55of23e	41	32	with	with	IN
work_knprvzmplre5lark3gt55of23e	41	33	concurrent	concurrent	JJ
work_knprvzmplre5lark3gt55of23e	41	34	thoracic	thoracic	NNP
work_knprvzmplre5lark3gt55of23e	41	35	radio-	radio-	NNP
work_knprvzmplre5lark3gt55of23e	41	36	therapy	therapy	NNP
work_knprvzmplre5lark3gt55of23e	41	37	(	(	-LRB-
work_knprvzmplre5lark3gt55of23e	41	38	4	4	CD
work_knprvzmplre5lark3gt55of23e	41	39	)	)	-RRB-
work_knprvzmplre5lark3gt55of23e	41	40	.	.	.
work_knprvzmplre5lark3gt55of23e	42	1	In	in	IN
work_knprvzmplre5lark3gt55of23e	42	2	a	a	DT
work_knprvzmplre5lark3gt55of23e	42	3	phase	phase	NN
work_knprvzmplre5lark3gt55of23e	42	4	II	II	NNP
work_knprvzmplre5lark3gt55of23e	42	5	trial	trial	NN
work_knprvzmplre5lark3gt55of23e	42	6	with	with	IN
work_knprvzmplre5lark3gt55of23e	42	7	gemcitabine	gemcitabine	NNP
work_knprvzmplre5lark3gt55of23e	42	8	(	(	-LRB-
work_knprvzmplre5lark3gt55of23e	42	9	600	600	CD
work_knprvzmplre5lark3gt55of23e	42	10	mg	mg	NNP
work_knprvzmplre5lark3gt55of23e	42	11	/	/	SYM
work_knprvzmplre5lark3gt55of23e	42	12	m2	m2	NNP
work_knprvzmplre5lark3gt55of23e	42	13	on	on	IN
work_knprvzmplre5lark3gt55of23e	42	14	d	d	NNP
work_knprvzmplre5lark3gt55of23e	42	15	1	1	CD
work_knprvzmplre5lark3gt55of23e	42	16	,	,	,
work_knprvzmplre5lark3gt55of23e	42	17	8)	8)	CD
work_knprvzmplre5lark3gt55of23e	42	18	and	and	CC
work_knprvzmplre5lark3gt55of23e	42	19	cisplatin	cisplatin	VB
work_knprvzmplre5lark3gt55of23e	42	20	given	give	VBN
work_knprvzmplre5lark3gt55of23e	42	21	concurrent	concurrent	JJ
work_knprvzmplre5lark3gt55of23e	42	22	with	with	IN
work_knprvzmplre5lark3gt55of23e	42	23	thoracic	thoracic	NNP
work_knprvzmplre5lark3gt55of23e	42	24	radiotherapy	radiotherapy	NNP
work_knprvzmplre5lark3gt55of23e	42	25	,	,	,
work_knprvzmplre5lark3gt55of23e	42	26	grade	grade	NNP
work_knprvzmplre5lark3gt55of23e	42	27	3	3	CD
work_knprvzmplre5lark3gt55of23e	42	28	-	-	SYM
work_knprvzmplre5lark3gt55of23e	42	29	4	4	CD
work_knprvzmplre5lark3gt55of23e	42	30	dyspnea	dyspnea	NN
work_knprvzmplre5lark3gt55of23e	42	31	was	be	VBD
work_knprvzmplre5lark3gt55of23e	42	32	observed	observe	VBN
work_knprvzmplre5lark3gt55of23e	42	33	in	in	IN
work_knprvzmplre5lark3gt55of23e	42	34	14	14	CD
work_knprvzmplre5lark3gt55of23e	42	35	of	of	IN
work_knprvzmplre5lark3gt55of23e	42	36	62	62	CD
work_knprvzmplre5lark3gt55of23e	42	37	(	(	-LRB-
work_knprvzmplre5lark3gt55of23e	42	38	23	23	CD
work_knprvzmplre5lark3gt55of23e	42	39	%	%	NN
work_knprvzmplre5lark3gt55of23e	42	40	)	)	-RRB-
work_knprvzmplre5lark3gt55of23e	42	41	of	of	IN
work_knprvzmplre5lark3gt55of23e	42	42	participants	participant	NNS
work_knprvzmplre5lark3gt55of23e	42	43	(	(	-LRB-
work_knprvzmplre5lark3gt55of23e	42	44	5	5	CD
work_knprvzmplre5lark3gt55of23e	42	45	)	)	-RRB-
work_knprvzmplre5lark3gt55of23e	42	46	.	.	.
work_knprvzmplre5lark3gt55of23e	43	1	Taxanes	taxane	NNS
work_knprvzmplre5lark3gt55of23e	43	2	The	the	DT
work_knprvzmplre5lark3gt55of23e	43	3	taxanes	taxane	NNS
work_knprvzmplre5lark3gt55of23e	43	4	,	,	,
work_knprvzmplre5lark3gt55of23e	43	5	paclitaxel	paclitaxel	NNP
work_knprvzmplre5lark3gt55of23e	43	6	and	and	CC
work_knprvzmplre5lark3gt55of23e	43	7	docetaxel	docetaxel	NNP
work_knprvzmplre5lark3gt55of23e	43	8	,	,	,
work_knprvzmplre5lark3gt55of23e	43	9	are	be	VBP
work_knprvzmplre5lark3gt55of23e	43	10	widely	widely	RB
work_knprvzmplre5lark3gt55of23e	43	11	used	use	VBN
work_knprvzmplre5lark3gt55of23e	43	12	in	in	IN
work_knprvzmplre5lark3gt55of23e	43	13	treatment	treatment	NN
work_knprvzmplre5lark3gt55of23e	43	14	of	of	IN
work_knprvzmplre5lark3gt55of23e	43	15	lung	lung	NN
work_knprvzmplre5lark3gt55of23e	43	16	cancer	cancer	NN
work_knprvzmplre5lark3gt55of23e	43	17	.	.	.
work_knprvzmplre5lark3gt55of23e	44	1	Acute	acute	JJ
work_knprvzmplre5lark3gt55of23e	44	2	type	type	NN
work_knprvzmplre5lark3gt55of23e	44	3	I	-PRON-	PRP
work_knprvzmplre5lark3gt55of23e	44	4	hypersensitivity	hypersensitivity	VBP
work_knprvzmplre5lark3gt55of23e	44	5	reaction	reaction	NN
work_knprvzmplre5lark3gt55of23e	44	6	with	with	IN
work_knprvzmplre5lark3gt55of23e	44	7	paclitaxel	paclitaxel	NNP
work_knprvzmplre5lark3gt55of23e	44	8	are	be	VBP
work_knprvzmplre5lark3gt55of23e	44	9	well	well	RB
work_knprvzmplre5lark3gt55of23e	44	10	known	known	JJ
work_knprvzmplre5lark3gt55of23e	44	11	.	.	.
work_knprvzmplre5lark3gt55of23e	45	1	Pulmonary	pulmonary	JJ
work_knprvzmplre5lark3gt55of23e	45	2	infiltrates	infiltrate	VBZ
work_knprvzmplre5lark3gt55of23e	45	3	following	follow	VBG
work_knprvzmplre5lark3gt55of23e	45	4	treatment	treatment	NN
work_knprvzmplre5lark3gt55of23e	45	5	have	have	VBP
work_knprvzmplre5lark3gt55of23e	45	6	been	be	VBN
work_knprvzmplre5lark3gt55of23e	45	7	reported	report	VBN
work_knprvzmplre5lark3gt55of23e	45	8	in	in	IN
work_knprvzmplre5lark3gt55of23e	45	9	low	low	JJ
work_knprvzmplre5lark3gt55of23e	45	10	frequency	frequency	NN
work_knprvzmplre5lark3gt55of23e	45	11	with	with	IN
work_knprvzmplre5lark3gt55of23e	45	12	paclitaxel	paclitaxel	NNP
work_knprvzmplre5lark3gt55of23e	45	13	and	and	CC
work_knprvzmplre5lark3gt55of23e	45	14	somewhat	somewhat	RB
work_knprvzmplre5lark3gt55of23e	45	15	more	more	JJR
work_knprvzmplre5lark3gt55of23e	45	16	cases	case	NNS
work_knprvzmplre5lark3gt55of23e	45	17	following	follow	VBG
work_knprvzmplre5lark3gt55of23e	45	18	docetaxel	docetaxel	NNP
work_knprvzmplre5lark3gt55of23e	45	19	treatment	treatment	NN
work_knprvzmplre5lark3gt55of23e	45	20	.	.	.
work_knprvzmplre5lark3gt55of23e	46	1	Docetaxel	Docetaxel	NNP
work_knprvzmplre5lark3gt55of23e	46	2	has	have	VBZ
work_knprvzmplre5lark3gt55of23e	46	3	also	also	RB
work_knprvzmplre5lark3gt55of23e	46	4	been	be	VBN
work_knprvzmplre5lark3gt55of23e	46	5	associated	associate	VBN
work_knprvzmplre5lark3gt55of23e	46	6	with	with	IN
work_knprvzmplre5lark3gt55of23e	46	7	the	the	DT
work_knprvzmplre5lark3gt55of23e	46	8	development	development	NN
work_knprvzmplre5lark3gt55of23e	46	9	of	of	IN
work_knprvzmplre5lark3gt55of23e	46	10	pleural	pleural	JJ
work_knprvzmplre5lark3gt55of23e	46	11	effusions	effusion	NNS
work_knprvzmplre5lark3gt55of23e	46	12	.	.	.
work_knprvzmplre5lark3gt55of23e	47	1	The	the	DT
work_knprvzmplre5lark3gt55of23e	47	2	combination	combination	NN
work_knprvzmplre5lark3gt55of23e	47	3	of	of	IN
work_knprvzmplre5lark3gt55of23e	47	4	docetaxel	docetaxel	NNP
work_knprvzmplre5lark3gt55of23e	47	5	and	and	CC
work_knprvzmplre5lark3gt55of23e	47	6	gemcitabine	gemcitabine	NNP
work_knprvzmplre5lark3gt55of23e	47	7	has	have	VBZ
work_knprvzmplre5lark3gt55of23e	47	8	been	be	VBN
work_knprvzmplre5lark3gt55of23e	47	9	tested	test	VBN
work_knprvzmplre5lark3gt55of23e	47	10	in	in	IN
work_knprvzmplre5lark3gt55of23e	47	11	a	a	DT
work_knprvzmplre5lark3gt55of23e	47	12	phase	phase	NN
work_knprvzmplre5lark3gt55of23e	47	13	II	II	NNP
work_knprvzmplre5lark3gt55of23e	47	14	trial	trial	NN
work_knprvzmplre5lark3gt55of23e	47	15	by	by	IN
work_knprvzmplre5lark3gt55of23e	47	16	Japan	Japan	NNP
work_knprvzmplre5lark3gt55of23e	47	17	Lung	Lung	NNP
work_knprvzmplre5lark3gt55of23e	47	18	Cancer	Cancer	NNP
work_knprvzmplre5lark3gt55of23e	47	19	Cooperative	Cooperative	NNP
work_knprvzmplre5lark3gt55of23e	47	20	Group	Group	NNP
work_knprvzmplre5lark3gt55of23e	47	21	.	.	.
work_knprvzmplre5lark3gt55of23e	48	1	They	-PRON-	PRP
work_knprvzmplre5lark3gt55of23e	48	2	observed	observe	VBD
work_knprvzmplre5lark3gt55of23e	48	3	an	an	DT
work_knprvzmplre5lark3gt55of23e	48	4	unexpectedly	unexpectedly	RB
work_knprvzmplre5lark3gt55of23e	48	5	high	high	JJ
work_knprvzmplre5lark3gt55of23e	48	6	rate	rate	NN
work_knprvzmplre5lark3gt55of23e	48	7	of	of	IN
work_knprvzmplre5lark3gt55of23e	48	8	grade	grade	NN
work_knprvzmplre5lark3gt55of23e	48	9	3	3	CD
work_knprvzmplre5lark3gt55of23e	48	10	interstitial	interstitial	JJ
work_knprvzmplre5lark3gt55of23e	48	11	lung	lung	NN
work_knprvzmplre5lark3gt55of23e	48	12	disease	disease	NN
work_knprvzmplre5lark3gt55of23e	48	13	of	of	IN
work_knprvzmplre5lark3gt55of23e	48	14	11	11	CD
work_knprvzmplre5lark3gt55of23e	48	15	%	%	NN
work_knprvzmplre5lark3gt55of23e	48	16	(	(	-LRB-
work_knprvzmplre5lark3gt55of23e	48	17	7	7	CD
work_knprvzmplre5lark3gt55of23e	48	18	of	of	IN
work_knprvzmplre5lark3gt55of23e	48	19	63	63	CD
work_knprvzmplre5lark3gt55of23e	48	20	patients	patient	NNS
work_knprvzmplre5lark3gt55of23e	48	21	)	)	-RRB-
work_knprvzmplre5lark3gt55of23e	48	22	with	with	IN
work_knprvzmplre5lark3gt55of23e	48	23	this	this	DT
work_knprvzmplre5lark3gt55of23e	48	24	combina-	combina-	JJ
work_knprvzmplre5lark3gt55of23e	48	25	tion	tion	NN
work_knprvzmplre5lark3gt55of23e	48	26	(	(	-LRB-
work_knprvzmplre5lark3gt55of23e	48	27	6	6	CD
work_knprvzmplre5lark3gt55of23e	48	28	)	)	-RRB-
work_knprvzmplre5lark3gt55of23e	48	29	.	.	.
work_knprvzmplre5lark3gt55of23e	49	1	Others	other	NNS
work_knprvzmplre5lark3gt55of23e	49	2	have	have	VBP
work_knprvzmplre5lark3gt55of23e	49	3	also	also	RB
work_knprvzmplre5lark3gt55of23e	49	4	reported	report	VBN
work_knprvzmplre5lark3gt55of23e	49	5	high	high	JJ
work_knprvzmplre5lark3gt55of23e	49	6	pulmonary	pulmonary	JJ
work_knprvzmplre5lark3gt55of23e	49	7	toxicity	toxicity	NN
work_knprvzmplre5lark3gt55of23e	49	8	with	with	IN
work_knprvzmplre5lark3gt55of23e	49	9	this	this	DT
work_knprvzmplre5lark3gt55of23e	49	10	combination	combination	NN
work_knprvzmplre5lark3gt55of23e	49	11	.	.	.
work_knprvzmplre5lark3gt55of23e	50	1	Sekine	Sekine	NNP
work_knprvzmplre5lark3gt55of23e	50	2	and	and	CC
work_knprvzmplre5lark3gt55of23e	50	3	associates	associate	NNS
work_knprvzmplre5lark3gt55of23e	50	4	observed	observe	VBD
work_knprvzmplre5lark3gt55of23e	50	5	pneumonitis	pneumonitis	RB
work_knprvzmplre5lark3gt55of23e	50	6	in	in	IN
work_knprvzmplre5lark3gt55of23e	50	7	24	24	CD
work_knprvzmplre5lark3gt55of23e	50	8	%	%	NN
work_knprvzmplre5lark3gt55of23e	50	9	(	(	-LRB-
work_knprvzmplre5lark3gt55of23e	50	10	14	14	CD
work_knprvzmplre5lark3gt55of23e	50	11	of	of	IN
work_knprvzmplre5lark3gt55of23e	50	12	59	59	CD
work_knprvzmplre5lark3gt55of23e	50	13	)	)	-RRB-
work_knprvzmplre5lark3gt55of23e	50	14	of	of	IN
work_knprvzmplre5lark3gt55of23e	50	15	Japanese	japanese	JJ
work_knprvzmplre5lark3gt55of23e	50	16	patients	patient	NNS
work_knprvzmplre5lark3gt55of23e	50	17	treated	treat	VBN
work_knprvzmplre5lark3gt55of23e	50	18	with	with	IN
work_knprvzmplre5lark3gt55of23e	50	19	consolidative	consolidative	JJ
work_knprvzmplre5lark3gt55of23e	50	20	docetaxel	docetaxel	NNP
work_knprvzmplre5lark3gt55of23e	50	21	fol-	fol-	NNP
work_knprvzmplre5lark3gt55of23e	50	22	lowing	low	VBG
work_knprvzmplre5lark3gt55of23e	50	23	concurrent	concurrent	JJ
work_knprvzmplre5lark3gt55of23e	50	24	chemoradiotherapy	chemoradiotherapy	NN
work_knprvzmplre5lark3gt55of23e	50	25	with	with	IN
work_knprvzmplre5lark3gt55of23e	50	26	other	other	JJ
work_knprvzmplre5lark3gt55of23e	50	27	agents	agent	NNS
work_knprvzmplre5lark3gt55of23e	50	28	(	(	-LRB-
work_knprvzmplre5lark3gt55of23e	50	29	7	7	CD
work_knprvzmplre5lark3gt55of23e	50	30	)	)	-RRB-
work_knprvzmplre5lark3gt55of23e	50	31	.	.	.
work_knprvzmplre5lark3gt55of23e	51	1	Similarly	similarly	RB
work_knprvzmplre5lark3gt55of23e	51	2	,	,	,
work_knprvzmplre5lark3gt55of23e	51	3	the	the	DT
work_knprvzmplre5lark3gt55of23e	51	4	Hoosier	Hoosier	NNP
work_knprvzmplre5lark3gt55of23e	51	5	Oncology	Oncology	NNP
work_knprvzmplre5lark3gt55of23e	51	6	Group	Group	NNP
work_knprvzmplre5lark3gt55of23e	51	7	reported	report	VBD
work_knprvzmplre5lark3gt55of23e	51	8	pulmonary	pulmonary	JJ
work_knprvzmplre5lark3gt55of23e	51	9	toxicity	toxicity	NN
work_knprvzmplre5lark3gt55of23e	51	10	in	in	IN
work_knprvzmplre5lark3gt55of23e	51	11	10	10	CD
work_knprvzmplre5lark3gt55of23e	51	12	%	%	NN
work_knprvzmplre5lark3gt55of23e	51	13	of	of	IN
work_knprvzmplre5lark3gt55of23e	51	14	patients	patient	NNS
work_knprvzmplre5lark3gt55of23e	51	15	receiving	receive	VBG
work_knprvzmplre5lark3gt55of23e	51	16	consolidative	consolidative	JJ
work_knprvzmplre5lark3gt55of23e	51	17	docetaxel	docetaxel	NNP
work_knprvzmplre5lark3gt55of23e	51	18	(	(	-LRB-
work_knprvzmplre5lark3gt55of23e	51	19	8)	8)	CD
work_knprvzmplre5lark3gt55of23e	51	20	.	.	.